<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acyclovir (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acyclovir (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Acyclovir (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8628" href="/d/html/8628.html" rel="external">see "Acyclovir (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12337" href="/d/html/12337.html" rel="external">see "Acyclovir (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7808291"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zovirax [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869053"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Acyclovir;</li>
<li>MINT-Acyclovir;</li>
<li>MYLAN-Acyclovir;</li>
<li>TEVA-Acyclovir;</li>
<li>Zovirax</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10456715"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent, Oral</span>;</li>
<li>
<span class="list-set-name">Antiviral Agent, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462650"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV) infection, treatment:</b>
<b>Note: </b>Duration of therapy depends on site of infection and clinical response; for CNS and disseminated infections, treat for ≥21 days; for skin and mucous membrane infections, treat for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-based dosing: </i>Preterm and term neonates: IV: 20 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359576','lexi-content-ref-Bradley.2','lexi-content-ref-11483782','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359576','lexi-content-ref-Bradley.2','lexi-content-ref-11483782','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postmenstrual age-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24346595','lexi-content-ref-Zydus.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24346595','lexi-content-ref-Zydus.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm and term neonates: IV: <b>Note: </b>Dosing is based on pharmacokinetic modeling and has not been evaluated prospectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24346595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24346595'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">PMA</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;30 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to &lt;36 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">36 to 41 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg/kg/dose every 6 to 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>HSV, chronic suppression following any HSV infection:</b> Limited data available: Preterm and term neonates: Oral: 300 mg/m<sup>2</sup>/dose every 8 hours for 6 months; begin after completion of IV treatment course; adjust dose monthly to account for growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359576','lexi-content-ref-Bradley.2','lexi-content-ref-21991950','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359576','lexi-content-ref-Bradley.2','lexi-content-ref-21991950','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella (chickenpox), treatment:</b> Limited data available; optimal dose has not been established:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: IV: 10 to 15 mg/kg/dose every 8 hours for 7 to 10 days; continue for ≥48 hours after the last new lesions have appeared; doses of 20 mg/kg/dose every 8 hours have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31263790','lexi-content-ref-31122930','lexi-content-ref-33748051','lexi-content-ref-9514106','lexi-content-ref-Permar.1','lexi-content-ref-17180380','lexi-content-ref-19097954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31263790','lexi-content-ref-31122930','lexi-content-ref-33748051','lexi-content-ref-9514106','lexi-content-ref-Permar.1','lexi-content-ref-17180380','lexi-content-ref-19097954'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing: Altered kidney function: Neonatal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2066845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2066845'])">Ref</a></span>): IV:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 25 to 50 mL/minute/1.73 m<sup>2 </sup>
<b>or </b>SCr 0.8 to 1.1 mg/dL: Administer the usual recommended dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;25 mL/minute/1.73 m<sup>2 </sup>
<b>or </b>SCr &gt;1.1 to 1.5 mg/dL: Administer the usual recommended dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute/1.73 m<sup>2 </sup>
<b>or </b>SCr &gt;1.5 mg/dL: Administer 50% of the usual recommended dose every 24 hours (eg, if the usual recommended dose is 10 mg/kg/dose every 8 hours, administer 5 mg/kg/dose every 24 hours).</p></div>
<div class="block dop drugH1Div" id="F7901184"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6d4ecdd-16ae-4b69-be83-3dc31168352e">Cytomegalovirus prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV) prophylaxis:</b> Low-risk allogeneic hematopoietic stem cell transplant (HSCT) in seropositive recipient. <b>Note:</b> Begin at engraftment and continue to day 100; requires close monitoring for CMV reactivation (due to weak activity); not for use in patients at high risk for CMV disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;40 kg: 600 mg/<b>m<sup>2</sup></b>/dose 4 times daily; maximum dose: 800 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≥40 kg: 800 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a4484d2-e95f-4283-9102-f9d873c8eed9">Varicella zoster virus, acute retinal necrosis, treatment, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, acute retinal necrosis, treatment, HIV-exposed/-infected:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment: <b>Note:</b> Follow up IV therapy with oral valacyclovir or acyclovir therapy (valacyclovir preferred) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 10 mg/kg/dose every 8 hours for 10 to 14 days; recommended to be used in combination with 1 to 2 doses of intravitreal ganciclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance treatment (alternative to valacyclovir): Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 4 to 6 weeks to begin after 10- to 14-day course of IV acyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e7bc6fa-f3f3-4346-982a-01ee6e4ad790">Herpes zoster, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompetent host: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Ambulatory therapy: Children ≥12 years and Adolescents: Oral: 800 mg every 4 hours (5 doses per day) for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hospitalized patient:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;2 years: IV: 10 mg/kg/dose every 8 hours for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 7 to 10 days; some experts recommend 10 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompromised host, non-HIV-exposed/-infected:</i> IV: Infants, Children, and Adolescents: 10 mg/kg/dose every 8 hours for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild, uncomplicated disease and no or moderate immune suppression:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 7 to 10 days; maximum dose: 800 mg/dose; consider longer course if resolution of lesions is slow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents (alternative therapy): Oral: 800 mg 5 times daily for 7 to 10 days, longer if lesions resolve slowly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe immune suppression or complicated disease; trigeminal nerve involvement, extensive multidermatomal zoster or extensive cutaneous lesions or visceral involvement:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: IV: 10 mg/kg/dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10- to 14-day total course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children: IV: 10 mg/kg/dose <b>or</b> 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10- to 14-day total course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: 10 mg/kg/dose every 8 hours until clinical improvement is evident, then convert to oral therapy to complete a 10- to 14-day total course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="528c2fa5-1da0-4e34-a34c-c892ae05c421">Herpes simplex virus neonatal infection, treatment and suppressive therapy in very young infants</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV) neonatal infection, treatment and suppressive therapy in very young infants (independent of HIV status):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (disseminated, CNS, or skin, eye, or mouth disease): Infants 1 to 3 months: IV: 20 mg/kg/dose every 8 hours; treatment duration: For cutaneous and mucous membrane infections (skin, eye, or mouth): 14 days; for CNS or disseminated infection: 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359576','lexi-content-ref-Bradley.1','lexi-content-ref-26042815','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359576','lexi-content-ref-Bradley.1','lexi-content-ref-26042815','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic suppressive therapy following any neonatal HSV infection: Infants: Oral: 300 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 6 months; begin after completion of a 14- to 21-day-course of IV therapy dependent upon type of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359576','lexi-content-ref-Bradley.1','lexi-content-ref-21991950','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359576','lexi-content-ref-Bradley.1','lexi-content-ref-21991950','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3fab333-4635-460f-8c84-2fa98f09da64">Herpes simplex virus encephalitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus encephalitis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Independent of HIV status:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 3 months to &lt;12 years: IV: 10 to 15 mg/kg/dose every 8 hours for 14 to 21 days. <b>Note:</b> Due to increased risk of neurotoxicity and nephrotoxicity, higher doses (20 mg/kg) are not routinely recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IV: 10 mg/kg/dose every 8 hours for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2b01a83-a4d2-4d7a-80a1-c067cbf6fbe0">Herpes simplex virus, genital infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, genital infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">First infection, mild to moderate:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 years: Oral: 40 to 80 mg/kg/<b>day</b> divided in 3 to 4 doses per day for 7 to 10 days; maximum daily dose: 1,200 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥12 years: Oral: 200 mg every 4 hours while awake (5 times daily) <b>or</b> 400 mg 3 times daily for 7 to 10 days; treatment can be extended beyond 10 days if healing is not complete (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children: Oral: 20 mg/kg/dose 3 times daily for 7 to 10 days; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 400 mg 3 times daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">First infection, severe (independent of HIV status): IV: Children and Adolescents ≥12 years: 5 mg/kg/dose every 8 hours for 5 to 7 days <b>or</b> 5 to 10 mg/kg/dose every 8 hours for 2 to 7 days, followed with oral therapy to complete at least 10 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent infection:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;12 years (independent of HIV status): Oral: 20 mg/kg/dose 3 times daily for 5 days; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≥12 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Non-HIV-exposed/-infected:</i> Oral: 200 mg every 4 hours while awake (5 times daily) for 5 days, <b>or</b> 400 mg 3 times daily for 5 days, <b>or</b> 800 mg twice daily for 5 days <b>or</b> 800 mg 3 times daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIV-exposed/-infected:</i> Adolescents: Oral: 400 mg 3 times daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Suppression, chronic:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 years: Limited data available: Oral: 20 mg/kg/dose twice daily; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥12 years: Oral: 400 mg twice daily; reassess therapy after 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-26042815','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-26042815','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>HIV-exposed/-infected: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 20 mg/kg/dose twice daily; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92900209-87cb-4e0e-afff-c4cc3cdf30a6">HSV orolabial disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HSV orolabial disease (ie, gingivostomatitis, herpes labialis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-HIV-exposed/-infected:</i> Primary infection: Infants, Children, and Adolescents: Oral: 20 mg/kg/dose 4 times daily for 5 to 7 days; usual maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Mild, symptomatic:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 7 to 10 days; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 400 mg 3 times daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe, symptomatic: <b>Note: </b>Switch to oral therapy once lesions begin to regress and continue oral therapy until lesions completely healed.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: IV: 5 to 10 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: 5 mg/kg/dose every 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc927598-72d2-4e9c-90f1-41398e5be5e9">Herpes simplex virus, mucocutaneous infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, mucocutaneous infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Immunocompetent host:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 5 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 20 mg/kg/dose 4 times daily for 5 to 7 days; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suppression, chronic: Limited data available; no pediatric data; some experts recommend oral 20 mg/kg/dose 2 to 3 times daily for 6 to 12 months, then reevaluate need; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompromised host: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children: IV: 10 mg/kg/dose every 8 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: IV: 5 to 10 mg/kg/dose every 8 hours; change to oral therapy after lesions begin to regress (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Children ≥2 years and Adolescents: 1,000 mg/<b>day</b> in 3 to 5 divided doses for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suppression, chronic (cutaneous, ocular) episodes:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Non-HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: Oral: 400 mg twice daily; reassess at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children: Oral: 20 mg/kg/dose twice daily; maximum dose: 800 mg/dose; reassess after 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: Oral: 400 mg twice daily; reassess at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6596d8d2-0a79-426a-a70b-fdd591d661f9">HSV progressive or disseminated infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HSV progressive or disseminated infection, treatment (immunocompromised host):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Non-HIV-exposed/-infected: Infants, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">HIV-exposed/-infected: Infants, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours for 21 days; higher doses (up to 20 mg/kg/dose) may be used in children &lt;12 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb809951-4fda-4f29-860b-477e21605286">HSV, acute retinal necrosis, treatment, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HSV, acute retinal necrosis, treatment, HIV-exposed/-infected:</b> Infants and Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment: IV: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days. <b>Note:</b> Follow up IV therapy with oral acyclovir or valacyclovir maintenance therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance treatment (alternative to valacyclovir): Begin after 10- to 14-day course of IV acyclovir: Oral: 20 mg/kg/dose 4 times daily for 4 to 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12108ff1-d13d-4906-9b58-4e92fd9d9c9a">HSV prophylaxis; immunocompromised hosts, seropositive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HSV prophylaxis; immunocompromised hosts, seropositive:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HSCT in seropositive recipient </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of early reactivation: <b>Note:</b> Begin at conditioning and continue until engraftment or resolution of mucositis; whichever is longer (~30 days post-HSCT)</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents &lt;40 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">IV: 250 mg/<b>m<sup>2</sup></b>/dose every 8 hours <b>or</b> 125 mg/<b>m<sup>2</sup></b>/dose every 6 hours; maximum daily dose: 80 mg/kg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">Oral: 60 to 90 mg/kg/<b>day</b> in 2 to 3 divided doses; maximum dose: 800 mg/dose twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥40 kg:</p>
<p style="text-indent:-2em;margin-left:10em;">IV: 250 mg/<b>m<sup>2</sup></b>/dose every 12 hours</p>
<p style="text-indent:-2em;margin-left:10em;">Oral: 400 to 800 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of late reactivation: <b>Note:</b> Treatment during first year after HSCT.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents &lt;40 kg: Oral: 60 to 90 mg/kg/<b>day</b> in 2 to 3 divided doses; maximum daily dose: 800 mg twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥40 kg: Oral: 800 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other immunocompromised hosts who are HSV seropositive: </i></p>
<p style="text-indent:-2em;margin-left:6em;">IV: Infants, Children, and Adolescents: 5 mg/kg/dose every 8 hours during period of risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Children ≥2 years and Adolescents: 200 mg every 4 hours while awake (5 doses daily) <b>or</b> 200 mg every 8 hours; administer during periods of risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ce04d33-b454-45c0-8f65-00c4fd84e740">Varicella or herpes zoster, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella (chickenpox) or herpes zoster (shingles), prophylaxis</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HSCT:</i> Prophylaxis of disease reactivation: <b>Note:</b> Continue therapy for 1 year after HSCT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;40 kg: Oral: 60 to 80 mg/kg/day in 2 to 3 divided doses</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≥40 kg: Oral: 800 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected:</i> Limited data available: <b>Note:</b> Consider use if &gt;96 hours postexposure or if VZV-immune globulin is not available; begin therapy 7 to 10 days after exposure; some experts begin therapy at first appearance of rash (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 7 days; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 800 mg 5 times daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other immunocompromised hosts:</i> Infants, Children, and Adolescents: Oral: 20 mg/kg/dose 4 times daily for 7 days; maximum dose: 800 mg/dose. <b>Note:</b> Consider use if VZV-immune globulin or IVIG is not available; begin therapy 7 to 10 days after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40e619db-9b16-405c-bbdf-57baadfec66c">Varicella, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella (chickenpox), treatment:</b> Begin treatment within the first 24 hours of rash onset:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompetent host: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Ambulatory therapy: Oral: Infants, Children, and Adolescents: 20 mg/kg/dose 4 times daily for 5 days; maximum daily dose: 3,200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hospitalized patient: IV: Infants, Children, and Adolescents: 10 mg/kg/dose <b>or</b> 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>); some experts recommend 15 to 20 mg/kg/dose for severe disseminated or CNS infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompromised host, non-HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;2 years: IV: 10 mg/kg/dose every 8 hours; duration dependent upon clinical response, typically 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours duration dependent upon clinical response, typically 7 to 14 days; some experts recommend 10 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild, uncomplicated disease and no or moderate immune suppression:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 7 to 10 days and until no new lesions for 48 hours; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents (alternative therapy): Oral: 800 mg 5 times daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe, complicated disease or severe immune suppression:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: IV: 10 mg/kg/dose every 8 hours for 7 to 10 days and until no new lesions for 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children: IV: 10 mg/kg/dose or 500 mg/m<sup>2</sup>/dose every 8 hours for 7 to 10 days or until no new lesions for 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: 10 mg/kg/dose every 8 hours for 7 to 10 days; may convert to oral therapy after defervescence and if no evidence of visceral involvement is evident (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51011123"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor closely for neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942005'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 25 to 50 mL/minute/1.73 m<sup>2</sup>: Administer the usual recommended dose every 12 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;25 mL/minute/1.73 m<sup>2</sup>: Administer the usual recommended dose every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of the usual recommended dose every 24 hours (eg, if the usual recommended dose is 10 mg/kg/dose every 8 hours, then administer 5 mg/kg/dose every 24 hours)</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis (IHD): Dialyzable (60% reduction following a 6-hour session): 5 mg/kg/dose every 24 hours; administer after hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): 5 mg/kg/dose every 24 hours; no supplemental dose needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p></div>
<div class="block dohp drugH1Div" id="F51011063"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F7901185"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8628" href="/d/html/8628.html" rel="external">see "Acyclovir (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>To avoid overdosing and subsequent toxicity (eg, acute renal failure), use ideal body weight or adjusted body weight for weight-based dosing in patients with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26824940','lexi-content-ref-27067742','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26824940','lexi-content-ref-27067742','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01d3e8c6-1ec1-4614-aae2-225baffa4c00">Bell palsy, new onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bell palsy, new onset (adjunctive therapy) (alternative agent) (off-label use): Oral:</b> 400 mg 5 times daily for 10 days in combination with corticosteroids; begin within 3 days of symptom onset. <b>Note:</b> Antiviral therapy alone is <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23136264','lexi-content-ref-24189771','lexi-content-ref-8651631','lexi-content-ref-17942873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23136264','lexi-content-ref-24189771','lexi-content-ref-8651631','lexi-content-ref-17942873'])">Ref</a></span>); some experts only recommend addition of an antiviral to steroid therapy in patients with severe Bell palsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24934895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24934895'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4821f121-1220-4d10-bf51-54fa660e92c2">Cytomegalovirus, prevention in recipients of allogeneic hematopoietic cell transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prevention in recipients of allogeneic hematopoietic cell transplant (alternative agent) (off-label use):</b>
<b>Note:</b> Begin at engraftment and continue to day 100; requires close monitoring for cytomegalovirus (CMV) reactivation (due to weak activity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours for up to 4 weeks or until hospital discharge, followed by oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-19299333','lexi-content-ref-11929799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-19299333','lexi-content-ref-11929799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Following initial IV therapy: 800 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-19299333','lexi-content-ref-11929799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-19299333','lexi-content-ref-11929799'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4f74dd8-496b-4769-89a5-938460877680">Herpes simplex virus, central nervous system infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, central nervous system infection (encephalitis or meningitis):</b>
<b>IV:</b> 10 mg/kg/dose every 8 hours. Duration for encephalitis is 14 to 21 days and for meningitis is 10 to 14 days; treatment of encephalitis requires IV therapy while treatment of meningitis may include step-down oral antiviral therapy. <b>Note:</b> Empiric herpes simplex virus (HSV) therapy should be initiated in all patients with suspected encephalitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-18582201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-18582201'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc927598-72d2-4e9c-90f1-41398e5be5e9">Herpes simplex virus, mucocutaneous infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, mucocutaneous infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Esophagitis (off-label use)</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent: <b>Oral:</b> 400 mg 3 times daily <b>or </b>200 mg 5 times daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.2020','lexi-content-ref-20616659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.2020','lexi-content-ref-20616659'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised: <b>Oral:</b> 400 mg 5 times daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with severe odynophagia or dysphagia: <b>IV:</b> 5 mg/kg/dose every 8 hours; patients who rapidly improve can be switched to an oral antiviral to complete a total of 7 to 14 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20616659','lexi-content-ref-34841008','lexi-content-ref-34729190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20616659','lexi-content-ref-34841008','lexi-content-ref-34729190'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Genital:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial episode</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 400 mg 3 times daily for 7 to 10 days; extend duration if lesions have not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV</b> (for severe disease): 5 to 10 mg/kg/dose every 8 hours; once clinically improved, may switch to oral antiviral therapy to complete &gt;10 days of therapy total (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, recurrent episode:</i>
<b>Oral:</b> 800 mg twice daily for 5 days <b>or </b>800 mg 3 times daily for 2 days. <b>Note</b>: Treatment is most effective when initiated during the prodrome or within 1 day of lesion onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences):</i>
<b>Oral:</b> 400 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised (including patients with HIV):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial <b>or</b> recurrent episode:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 400 mg 3 times daily for 5 to 10 days (7 to 10 days for initial episode in patients with HIV); extend treatment duration if lesions have not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV</b> (for severe disease): 5 to 10 mg/kg/dose every 8 hours; may transition to oral antiviral therapy once lesions begin to regress and continue for &gt;10 days of therapy and until complete resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences):</i>
<b>Oral:</b> 400 to 800 mg 2 to 3 times daily.<b> Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnant patients:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial episode:</i>
<b>Oral:</b> 400 mg 3 times daily for 7 to 10 days; extend treatment duration if lesion has not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, recurrent episode (symptomatic):</i>
<b>Oral:</b> 400 mg 3 times daily <b>or</b> 800 mg twice daily for 5 days <b>or</b> 800 mg 3 times daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414','lexi-content-ref-34292926'])">Ref</a></span>). <b>Note:</b> Some experts reserve treatment of recurrent episodes for patients with severe and/or frequent symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riley.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riley.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, severe or disseminated disease:</i>
<b>IV: </b>5 to 10 mg/kg every 8 hours for 2 to 7 days, then change to oral therapy for primary infection to complete 10 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy, for patients with a genital HSV lesion anytime during pregnancy:</i>
<b>Oral:</b> 400 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414','lexi-content-ref-34292926'])">Ref</a></span>), beginning at 36 weeks' gestation and continued until delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414','lexi-content-ref-34292926','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414','lexi-content-ref-34292926','lexi-content-ref-HHS.2023'])">Ref</a></span>); some experts recommend discontinuing suppressive therapy at the onset of labor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riley.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riley.2020'])">Ref</a></span>). <b>Note:</b> For patients with a primary infection during the third trimester, may consider suppressive therapy earlier than 36 weeks' gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Orolabial</i>:</b>
<b>Note:</b> Initiate therapy at earliest symptom.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent and immunocompromised (including patients with HIV):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment, initial <b>or</b> recurrent episode:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 400 mg 3 times daily for 5 to 10 days and until complete lesion resolution in patients who are immunocompromised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV</b> (for severe disease in immunocompromised patients): 5 mg/kg/dose every 8 hours; switch to oral acyclovir (or similar antiviral) once lesions begin to regress and continue until complete resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suppressive therapy (eg, for severe and/or frequent recurrences):</i>
<b>Oral:</b> 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2023','lexi-content-ref-8380540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2023','lexi-content-ref-8380540'])">Ref</a></span>). <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28cbc4d6-be78-4a44-8380-de87dfb2fee6">Herpes simplex virus, prevention in patients who are immunocompromised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, prevention in patients who are immunocompromised (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Seropositive hematopoietic cell transplant recipients (allogeneic or autologous) or seropositive patients undergoing leukemia induction chemotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 250 mg/<b>m<sup>2</sup></b>/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 to 800 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate with the chemotherapeutic or conditioning regimen and continue until recovery of WBC count and resolution of mucositis; duration may be extended in patients with frequent recurrences or graft-vs-host disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30179565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30179565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (HSV-seropositive patients who do<b> not </b>require CMV prophylaxis): <b>Oral:</b> 400 to 800 mg twice daily for ≥1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647'])">Ref</a></span>); some experts recommend continuing for 3 to 6 months after transplantation and during periods of lymphodepletion associated with treatment of rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fishman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fishman.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e7bc6fa-f3f3-4346-982a-01ee6e4ad790">Herpes zoster, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles), treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate at earliest sign or symptom. Antiviral treatment is most effective ≤72 hours after rash onset but may be initiated &gt;72 hours in certain situations (eg, new lesions continue to appear); for patients who are immunocompromised, initiate treatment even if &gt;72 hours after symptom onset unless all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10375341','lexi-content-ref-HHS.2023','lexi-content-ref-29746903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10375341','lexi-content-ref-HHS.2023','lexi-content-ref-29746903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute localized dermatomal lesion(s):</i>
<b>Oral:</b> 800 mg 5 times daily for 7 to 10 days; for slowly improving lesions, may extend therapy until resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2023'])">Ref</a></span>). For select patients who are immunocompromised at high risk of dissemination (eg, recent transplant, graft-versus-host disease), some experts suggest regimens used for disseminated zoster (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17143845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17143845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated zoster (extensive cutaneous lesions or visceral involvement):</i>
<b>IV:</b> 10 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2023'])">Ref</a></span>). When formation of new lesions has ceased and signs/symptoms of visceral infection are improving, switch to an oral antiviral to complete a total of 10 to 14 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40e619db-9b16-405c-bbdf-57baadfec66c">Varicella, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella (chickenpox), treatment:</b> Ideally initiate therapy within 24 hours of symptom onset, but may start later if the patient still has active lesions:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe or complicated infection:</i>
<b>IV:</b> 10 mg/kg/dose every 8 hours for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2023'])">Ref</a></span>). May switch to oral antiviral after defervescence if no evidence of visceral involvement; continue until all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Uncomplicated infection:</i>
<b>Oral:</b> 800 mg 5 times daily for ≥5 to 7 days and until all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8809466','lexi-content-ref-31162727','lexi-content-ref-HHS.2023','lexi-content-ref-1323943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8809466','lexi-content-ref-31162727','lexi-content-ref-HHS.2023','lexi-content-ref-1323943'])">Ref</a></span>). In patients who are immunocompromised (eg, solid organ transplant recipients), some experts recommend a minimum duration of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27347e7a-98ba-4a26-8be9-6bc5faf6fab4">Varicella zoster virus, acute retinal necrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, acute retinal necrosis (off-label use): IV:</b> 10 mg/kg/dose every 8 hours for 10 to 14 days, followed by prolonged valacyclovir; in patients with HIV, intravitreal ganciclovir may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a86324ca-1181-4af1-934e-8d5e4dd8b591">Varicella zoster virus, encephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, encephalitis (off-label use): IV:</b> 10 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18582201','lexi-content-ref-1538151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18582201','lexi-content-ref-1538151'])">Ref</a></span>); some experts use higher doses, up to 15 mg/kg/dose every 8 hours, although tolerability may be a limiting factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6343861','lexi-content-ref-18582201','lexi-content-ref-31081790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6343861','lexi-content-ref-18582201','lexi-content-ref-31081790'])">Ref</a></span>). The duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18582201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18582201'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3bb78c6-48fd-48c8-8b56-8e34a0dfab1d">Varicella zoster virus, prevention in patients who are immunocompromised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus, prevention in patients who are immunocompromised (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Seropositive hematopoietic cell transplant recipients (allogeneic and autologous): <b>Oral:</b> 800 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-16282339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-16282339'])">Ref</a></span>). <b>Note:</b> Initiate with the chemotherapeutic or conditioning regimen and continue for 1 year; may extend duration in patients requiring ongoing immunosuppression (some experts continue prophylaxis in these patients until 6 months after discontinuation of all systemic immunosuppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (patients who are VZV-seropositive who do<b> not</b> require CMV prophylaxis): <b>Oral:</b> 200 mg 3 to 5 times daily for 3 to 6 months after transplantation and during periods of lymphodepletion associated with treatment of rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-Fishman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-Fishman.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991158"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Monitor closely for neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942005'])">Ref</a></span>). For usual recommended doses not described in the following sections, a comparable reduction in the dose and/or frequency may be considered based on CrCl or the type of dialysis, taking into consideration the goals of therapy and the anticipated duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Acyclovir Dose Adjustments for Kidney Impairment<sup> a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl<sup>b</sup></p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Oral</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">IV</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">If the usual dose is <b>400 mg every 12 hours</b></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is <b>200 mg 5 times daily </b></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is <b>800 mg 5 times daily</b></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is <b>5 mg/kg/dose every 8 hours</b></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is <b>10 mg/kg/dose every 8 hours</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>a</sup>Recommendations are from manufacturer’s labeling unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>b</sup>The manufacturer's labeling dosing adjustments are reported as mL/minute/1.73 m<sup>2</sup> based on data using CrCl adjusted for BSA (Blum 1982; de Miranda 1983).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>c</sup>While toxicity is not likely to occur with an unadjusted dose in patients with a CrCl of 10 to 25 mL/minute/1.73 m<sup>2</sup> (as recommended in the manufacturer’s labeling), the exposure from the reduced dose is expected to be comparable to exposure achieved in patients receiving the usual recommended dose with normal kidney function (ie, CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>d</sup>Manufacturer’s labeling recommends 800 mg every 12 hours. However, due to reports of neurotoxicity in patients with end-stage kidney disease (Almond 1995; Beales 1994; Davenport 1992), a reduced dose is preferred (expert opinion).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>&gt;50 mL/minute/1.73 m<sup>2</sup></b></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>25 to 50 mL/minute/1.73 m<sup>2</sup></b></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>10 to &lt;25 mL/minute/1.73 m<sup>2</sup></b></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary or reduce to 200 mg every 12 hours<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary or reduce to 200 mg every 8 hours<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">800 mg every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>&lt;10 mL/minute/1.73 m<sup>2</sup> (not on dialysis)</b></p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg every 12 hours or 400 mg every 12 hours (severe infections)<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2.5 mg/kg/dose every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): IV, Oral:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Use the indication-specific maximum allowable dose along with therapeutic drug monitoring when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (60% reduction following a 6-hour session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7103443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7103443'])">Ref</a></span>)). Therapeutic drug monitoring of acyclovir is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 200 mg 5 times daily or 400 mg every 12 hours: Administer 200 mg every 12 hours. Administer after dialysis when given on a dialysis day or administer an additional dose after each dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 800 mg 5 times daily: Administer a loading dose of 400 mg, followed by a maintenance dose of 200 mg every 12 hours, plus an additional 400 mg dose after each dialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7777108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7777108'])">Ref</a></span>). <b>Note:</b> Dose based on pharmacokinetic data and computer modeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 to 5 mg/kg/dose every 24 hours. Administer after dialysis when given on a dialysis day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).<b> Note:</b> Use the higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Dialyzable (12% reduction during continuous ambulatory peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3624115']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3624115'])">Ref</a></span>)): Therapeutic drug monitoring of acyclovir is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 200 mg 5 times daily or 400 mg every 12 hours: Administer 200 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 800 mg 5 times daily: Administer 600 to 800 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8893152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8893152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 to 5 mg/kg/dose every 24 hours, no supplemental dose needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3624115','lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3624115','lexi-content-ref-Golightly.1'])">Ref</a></span>). <b>Note:</b> Use the higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important. Therapeutic drug monitoring of acyclovir is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9421114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9421114'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 10 mg/kg/dose every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9421114','lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9421114','lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Use the higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important. Therapeutic drug monitoring of acyclovir is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 10 mg/kg/dose every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). On non-PIRRT days, dose as for CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>. <b>Note:</b> Use the higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.</p></div>
<div class="block doha drugH1Div" id="F50988520"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe impairment.</p></div>
<div class="block arsc drugH1Div" id="F54964689"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acyclovir may cause <b>acute kidney injury</b>, resulting most often from obstructive nephropathy but may also be due to <b>interstitial nephritis</b> or <b>renal tubular necrosis</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30428841','lexi-content-ref-20862348','lexi-content-ref-30741619','lexi-content-ref-25708691','lexi-content-ref-33658895','lexi-content-ref-32404442','lexi-content-ref-33956193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30428841','lexi-content-ref-20862348','lexi-content-ref-30741619','lexi-content-ref-25708691','lexi-content-ref-33658895','lexi-content-ref-32404442','lexi-content-ref-33956193'])">Ref</a></span>). Kidney injury is reversible in most cases after dosage reduction or discontinuation; however, some cases may not return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619','lexi-content-ref-25708691','lexi-content-ref-30083888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619','lexi-content-ref-25708691','lexi-content-ref-30083888'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; not clearly established, multiple proposed mechanisms. Usually attributed to the formation of acyclovir crystals, which result in intrarenal obstruction and nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32549883','lexi-content-ref-10225250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32549883','lexi-content-ref-10225250'])">Ref</a></span>). May also be due to glomerular hyperfiltration; injury may occur because kidneys have little reserve, resulting in an intolerance to nephrotoxic insult or increased filtrate delivery to the renal tubules (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32404442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32404442'])">Ref</a></span>). Other proposed mechanisms include an immune reaction that may contribute to interstitial nephritis and a major metabolite of acyclovir (9-carboxymethoxymethylguanine [CMMG]) that may be directly cytotoxic to cells of the renal tubule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22005269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22005269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most commonly occurred within 3 days of initiation in adult and pediatric patients, but has also been reported later in therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619','lexi-content-ref-33658895','lexi-content-ref-25708691','lexi-content-ref-30083888','lexi-content-ref-32404442','lexi-content-ref-33956193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619','lexi-content-ref-33658895','lexi-content-ref-25708691','lexi-content-ref-30083888','lexi-content-ref-32404442','lexi-content-ref-33956193'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adult patients:</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid infusion of high dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Intravenous administration (due to higher bioavailability of acyclovir/valacyclovir); although cases during oral therapy have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23312723','lexi-content-ref-14606623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23312723','lexi-content-ref-14606623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30083888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30083888'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of nephrotoxic agents (eg, nonsteroidal anti-inflammatory drugs, vancomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30741619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30741619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:8em;">• Doses &gt;500 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Doses &gt;15 mg/kg (associated with a 25% to 49% reduction in eGFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;8 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691','lexi-content-ref-33956193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691','lexi-content-ref-33956193'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Weight &gt;20 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• BMI &gt;19 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent ceftriaxone with or without gadolinium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25708691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25708691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of nephrotoxic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32037154','lexi-content-ref-33956193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32037154','lexi-content-ref-33956193'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Glomerular hyperfiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32404442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32404442'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-induced neurotoxicity most commonly includes reported symptoms such as <b>agitation, confusion</b>, <b>dysarthria, hallucination</b>, and <b>impaired consciousness</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25440915','lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-36601749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25440915','lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-36601749'])">Ref</a></span>). Other reported symptoms include <b>aphasia</b>, <b>ataxia,</b>
<b>myoclonus</b>, <b>tremor,</b> and <b>seizure</b> (including status epilepticus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24368610','lexi-content-ref-31171414','lexi-content-ref-30669921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24368610','lexi-content-ref-31171414','lexi-content-ref-30669921'])">Ref</a></span>). Most cases of neurotoxicity are reversible after discontinuation with or without hemodialysis; however, some cases may not be fully reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-30669921','lexi-content-ref-36601749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794437','lexi-content-ref-34146428','lexi-content-ref-34713692','lexi-content-ref-32943113','lexi-content-ref-30669921','lexi-content-ref-36601749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; indirect, via metabolite 9-carboxymethoxymethylguanine accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically reported within 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34146428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34146428'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31504577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31504577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25440915','lexi-content-ref-34146428','lexi-content-ref-16540518','lexi-content-ref-31504577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25440915','lexi-content-ref-34146428','lexi-content-ref-16540518','lexi-content-ref-31504577'])">Ref</a></span>); however, some cases have been reported in normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31171414','lexi-content-ref-12799156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31171414','lexi-content-ref-12799156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25440915','lexi-content-ref-34146428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25440915','lexi-content-ref-34146428'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Damage to the blood-brain barrier (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31504577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31504577'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombotic microangiopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombotic thrombocytopenic purpura</b> (TTP) and <b>hemolytic-uremic syndrome</b> (HUS), manifestations of thrombotic microangiopathy, have been reported with both acyclovir and valacyclovir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9352739','lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9352739','lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274'])">Ref</a></span>). TTP/HUS may result in damage to the brain, heart, kidney, liver, and pancreas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12192020','lexi-content-ref-24237985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12192020','lexi-content-ref-24237985'])">Ref</a></span>). Resolution has been reported with discontinuation and appropriate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32550073','lexi-content-ref-28356666','lexi-content-ref-10847274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Idiosyncratic; thrombotic microangiopathy (and resulting TTP and HUS) involves endothelial cell injury, intravascular platelet-fibrin thrombi, and vascular damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24237985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24237985'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported within 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356666'])">Ref</a></span>) and after 1 year of therapy (case with valacyclovir) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32550073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32550073'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (largely unknown):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic susceptibility may play a role for drug-induced HUS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24237985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24237985'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F7808308"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with IV administration, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decrease in absolute neutrophil count (neonates: 3% to 16%), decreased hemoglobin (neonates: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise (oral: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤2%), skin rash (≤2%), urticaria (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral: 2% to 3%; IV: &lt;1%), nausea (oral and IV: ≤7%), vomiting (oral and IV: ≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (neonates: 5% to 10%; children, adolescents, and adults: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (neonates, grades 3/4: 4%), increased serum transaminases (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (≤9%), injection-site phlebitis (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (5% to 10%), increased serum creatinine (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Anemia, leukocytosis, neutropenia, neutrophilia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Anorexia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Kubin 2016), alopecia (Sharma 2016), bullous rash (Gurkan 2012), contact dermatitis (topical) (Vernassiere 2003), erythema multiforme, fixed drug eruption (Lee 2016), skin photosensitivity (topical) (Rodriguez-Serna 1999), Stevens-Johnson syndrome (Sen 2020), toxic epidermal necrolysis (Sen 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (Meng 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation, hemolysis, hemolytic-uremic syndrome (Bell 1997), leukopenia, lymphadenopathy, thrombotic microangiopathy (Goli 2017), thrombotic thrombocytopenic purpura (Bell 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hyperbilirubinemia, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Jen 2011), hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation (Brandariz-Nuñez 2021), aphasia (Patel 2019), ataxia (Patel 2019), coma, confusion (Brandariz-Nuñez 2021), delirium (Rashiq 1993), dizziness, drowsiness, dysarthria (Brandariz-Nuñez 2021), encephalopathy, fatigue, hallucination (Brandariz-Nuñez 2021), impaired consciousness (Brandariz-Nuñez 2021), myoclonus (Umoru 2020), obtundation (Marks 2020), pain, paresthesia, psychosis, seizure (Hoskote 2016), tremor (Patel 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Lee 2018), interstitial nephritis (Pańczyk-Tomaszewska 2020), kidney disease (obstructive nephropathy) (Fleischer 2010), renal tubular necrosis (Chávez-Iñiguez 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F7901079"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F7908330"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Acyclovir IV is an irritant (depending on concentration); avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Varicella: Appropriate use: For maximum benefit, treatment should begin within 24 hours of appearance of rash; oral route not recommended for routine use in otherwise healthy children with varicella but may be effective in patients at increased risk of moderate to severe infection (&gt;12 years of age, chronic cutaneous or pulmonary disorders, long-term salicylate therapy, corticosteroid therapy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Use IV preparation with caution in patients with underlying neurologic abnormalities, serious hepatic or electrolyte abnormalities, or substantial hypoxia. Encephalopathic changes characterized by lethargy, obtundation, confusion, hallucination, tremors, agitation, seizure, or coma have been observed in patients receiving IV acyclovir.</p></div>
<div class="block foc drugH1Div" id="F7901193"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (20 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zovirax: 200 mg/5 mL (473 mL [DSC]) [contains methylparaben, propylparaben; banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zovirax: 400 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zovirax: 800 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg, 800 mg</p></div>
<div class="block geq drugH1Div" id="F7908323"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F7912078"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Acyclovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.13 - $1.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Acyclovir Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $0.52 - $2.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Acyclovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $0.94 - $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Acyclovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.21 - $2.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $0.36 - $4.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869054"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zovirax: 200 mg/5 mL (125 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 400 mg, 800 mg</p></div>
<div class="block adip drugH1Div" id="F53569668"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Sodium content of 1 g: 5.1 mEq</p></div>
<div class="block admp drugH1Div" id="F52614311"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with or without food; shake suspension well before use. Maintain adequate hydration during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by slow IV infusion over at least 1 hour; rapid infusion is associated with nephrotoxicity due to crystalluria and renal tubular damage and should be avoided. Maintain adequate hydration during therapy. Do not administer IV push, IM, or SUBQ.</p>
<p style="text-indent:-2em;margin-left:4em;">Acyclovir IV may be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during IV infusion; avoid extravasation. If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote in addition to supportive management for refractory cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F7808318"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Avoid rapid infusion; infuse over 1 hour to prevent renal damage; maintain adequate hydration of patient; check for phlebitis and rotate infusion sites. Do not administer IM or SUBQ.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management</b>
<b>:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote for refractory cases in addition to supportive management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F7882924"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, oral suspension, tablet: Store at controlled room temperature of 15°C to 25°C (59°F to 77°F); protect capsule and tablet from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Store undiluted vials at 15°C to 25°C (59°F to 77°F). Following reconstitution (final concentration 50 mg/mL), solution is stable for 12 hours at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for injection: Store solution at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Do not refrigerate reconstituted solutions or solutions diluted for infusion as they may precipitate. Once diluted for infusion with NS or D5W, use within 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53570413"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of initial and prophylaxis of recurrent mucosal and cutaneous herpes simplex (HSV 1 and HSV 2) infections in immunocompromised patients (FDA approved in all ages); treatment of severe initial episodes of herpes genitalis in immunocompetent patients (FDA approved in ages ≥12 years and adults); treatment of herpes simplex encephalitis, including neonatal herpes simplex virus (FDA approved in all ages); treatment of herpes zoster (shingles) infections in immunocompromised patients (FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of varicella (chickenpox) in immunocompetent patients (FDA approved in ages ≥2 years and adults); treatment of initial episodes and prophylaxis of recurrent herpes simplex (HSV 2, genital herpes) and acute treatment of herpes zoster (shingles) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for treatment of varicella-zoster infections in healthy, nonpregnant persons &gt;13 years of age, children &gt;12 months of age who have a chronic skin or lung disorder or are receiving long-term aspirin therapy, and immunocompromised patients; oral therapy has also been used for suppression following parenteral treatment of neonatal HSV infection.</p></div>
<div class="block mst drugH1Div" id="F7808290"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Acyclovir may be confused with famciclovir, ganciclovir, Retrovir, valacyclovir, valganciclovir</p>
<p style="text-indent:-2em;margin-left:4em;">Zovirax may be confused with Doribax, Valtrex, Zithromax, Zostrix, Zyloprim, Zyvox</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298682"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, OCT1; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F7911154"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Acyclovir-Valacyclovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Systemic): Acyclovir (Systemic) may enhance the nephrotoxic effect of Netilmicin (Systemic). Acyclovir (Systemic) may enhance the neurotoxic effect of Netilmicin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Live/Attenuated): Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F7901189"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F7908327"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Acyclovir crosses the placenta (Frenkel 1991; Henderson 1992; Kimberlin 1998).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry established in 1984 and closed in 1999 included 749 pregnancies with 756 known outcomes following first trimester acyclovir exposure. Data from the registry did not find an increase in the number of birth defects with exposure to acyclovir when compared to those expected in the general population. In addition, no pattern of birth defects was observed (Stone 2004). A population-based registry study conducted in Denmark had similar results. The study used data from 1996 to 2008 and included 1,561 pregnancies with first trimester acyclovir exposure; an increased risk of birth defects was not observed (Pasternak 2010). One study observed an increased risk of gastroschisis following use of antiherpetic medications such as acyclovir during the first trimester to treat maternal genital herpes; this risk was also increased in offspring of women with genital herpes not receiving treatment (Ahrens 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, the pharmacokinetic properties of acyclovir may be altered in some women (Brocklehurst 1998; Frenkel 1991; Kimberlin 1998; Leung 2009). Dose adjustments are required for suppressive therapy and recurrent infections during pregnancy due to increased renal clearance (ACOG 2020). Acyclovir is associated with adverse effects on renal function; this risk may be increased with IV administration to patients during the third trimester of pregnancy (Boujenah 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Acyclovir is recommended for the treatment of genital herpes simplex virus (HSV) in pregnant patients (ACOG 2020; CDC [Workowski 2021]). Primary HSV infection during the first trimester may be associated with neonatal chorioretinitis, microcephaly, and skin lesions. The risk of perinatal transmission is greater when the primary infection occurs during pregnancy. Maternal treatment decreases duration and severity of disease and duration of viral shedding (ACOG 2020). Suppressive therapy is recommended for patients beginning at 36 weeks' gestation who have a history of genital lesions (ACOG 2020; CDC [Workowski 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Acyclovir is also recommended for the treatment of varicella (chickenpox) in pregnant patients. When treatment is started within 24 hours of rash development, acyclovir reduces the duration and total number of maternal lesions; however, it does not prevent congenital varicella syndrome (ACOG 2015).</p></div>
<div class="block mopp drugH1Div" id="F53570395"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urine output, volume status, BUN, SCr, urinalysis; liver enzymes; CBC (including neutrophil count at least twice weekly in neonates receiving 60 mg/kg/day [Kimberlin 2001]). When using high doses, monitor for signs and symptoms of neurotoxicity (eg, lethargy, confusion, hallucinations, tremors, myoclonus, seizures, extrapyramidal signs, changes in state of consciousness) (Whitley 2012).</p></div>
<div class="block pha drugH1Div" id="F7908334"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.</p></div>
<div class="block phk drugH1Div" id="F7808316"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Poorly absorbed; absorption improves with multiple small doses compared to one large daily dose (de Miranda 1983).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely (eg, brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, CSF) (de Miranda 1983; Laskin 1983); CSF acyclovir concentration is ~50% of plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (Sampson 2014; manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:8em;">PMA &lt;30 weeks: Median: 2.88 L/kg (range: 0.646 to 5.3 L/kg).</p>
<p style="text-indent:-2em;margin-left:8em;">PMA 30 to &lt;36 weeks: Median: 4.49 L/kg (range: 1.87 to 10.85 L/kg).</p>
<p style="text-indent:-2em;margin-left:8em;">PMA 36 to 41 weeks: Median: 2.55 L/kg (range: 0.293 to 4.09 L/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;3 months: 1.08 ± 0.35 L/kg (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months and Children: 1.01 ± 0.28 L/kg (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.8 ± 0.18 L/kg (Spector 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 9% to 33%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted by viral enzymes to acyclovir monophosphate, and further converted to diphosphate then triphosphate (active form) by cellular enzymes.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 10% to 20% with normal renal function (bioavailability decreases with increased dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (Sampson 2014):</p>
<p style="text-indent:-2em;margin-left:6em;">PMA &lt;30 weeks: Median: 10.2 hours (range: 4.73 to 13.2 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA 30 to 35 weeks: Median: 6.55 hours (range: 4.28 to 9.26 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">PMA 36 to 41 weeks: Median: 3 hours (range: 1.61 to 3.69 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≤3 months: 3.8 ± 1.19 hours (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months and Children: 2.36 ± 0.97 hours (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~2.5 hours (with normal renal function); 20 hours (ESRD) (Gorlitsky 2017); Hemodialysis: ~5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (62% to 91% as unchanged drug and metabolite).</p></div>
<div class="block phksp drugH1Div" id="F51219890"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Total body clearance and half-life are dependent on renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961951"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Acic | Acyclovir sodium | Clovir | Cycloviral | Lovir | Lovrak | Medvirox | Supraviran | Virpes | Virustat | Zovirax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acerpes | Aciclo ahimsa | Aciclovir filaxis | Aciclovir gemepe | Aciclovir lafedar | Aciclovir martian | Aciclovir Norgreen | Aciclovir northia | Duolip | Fada aciclovir | Kloviracil | Lafevir | Lisovyr | Lixar | Poviral | Trixviral | Virostatic | Xiclovir | Zovirax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aciclobene | Aciclostad | Aciclotyrol | Aciclovir | Aciclovir genericon pharma | Aciclovir-1a | Nycovir | Viromed | Xorox | Zovirax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir accord | Aciclovir an | Aciclovir generic health | Aciclovir sandoz | Aciclovir-bc | Acihexal | Acyclo v | Apo-aciclovir | Cm aciclovir | Genrx aciclovir | Lovir | Ozvir | Tw aciclovir | Zovirax | Zyclir</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acerux | Acyvir | Clovir | Novirax | Simplovir | Virux | Xovir | Zovirax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir ab | Aciclovir Bexal | Aciclovir eg | Aciclovir eurogenerics | Aciclovir Kela | Aciclovir mayne pharma (ben) | Aciclovir mylan | Aciclovir sandoz | Aciclovir teva generics belgium | Avirodine | Docaciclo | Viratop | Zovirax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir denk | Acyclovir</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Acic | Herpex | Medovir | Virolex | Zovirax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acibio | Aciclofar | Aciclomed | Aciclor | Aciclovan | Aciclovir | Aciclovir eurofarma | Aciclovir sodico | Aciveral | Acivirax | Anclomax | Antivirax | Aviral | Aziclor | Aziclovir | Ciclavix | Ciclocris | Clovantax | Clovir | Ductovirax | Exavir | Ezopen | Fasys | Heclivir | Herp-trat | Herpesil | Hervirax | Herzov | Hpmix | Hpvir | Lfm aciclovir | Uni vir | Verac | Virotin | Zelnin | Zovirax | Zoylex | Zynvir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir Labatec | Zovirax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir generis | Alovir | Lovir | Mevirox | Ocuvir | Wariviron | Zovirax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Cloviran | Deovir | Eurovir | Inmerax | Lisovyr | Sitoxan | Vironida | Zensavir | Zovirax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A lun | A nan sheng | Aciclovir | Aciclovir And Glucose | Aciclovir and sodium chloride | Aciclovir and sodium chloride injection(ii) | Acyclovir | Ai er xin | Ai wei da | Bang na | Bi rui | De er li wei | He gu | Ji min wei xin | Jian shi liao | Jiang ni | Jie luo wei | Kang da wei | Keduxing | Li ke ping | Li ke xin | Li zhu ke du xing | Qing lin | Sen di | Sha wei luo | Sheng nuo wei | Tian cheng xi er | Virless | Wei xin | Yi ke ling | Yi si ling | Zhu li | Zovirax | Zylovir</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir ag | Aciclovir BCN | Aciclovir mk | Activiral | Acyclovir Memphis | Alviret | Aviral | Carbaprof | Cicloviral | Dranicol | Herpevir | Hexidol | Isavir | Viclovir | Vilvex | Viralend | Vircidal | Virex | Virex z | Virex-Z | Virobis | Viroxil | Zovirax</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir Raven</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir AL | Aciclovir aurovitas | Aciclovir olikla | Herpesin | Provirsan | Ranvir | Xorox | Zirvin | Zovirax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ab aciclovir | Acerpes | Acic | Aciclo | Aciclobeta | Aciclostad | Aciclovir | Aciclovir Aristo | Aciclovir Heumann | Aciclovir hikma | Aciclovir puren | Aciclovir ratiopharm | Acivir | Acyclovir denk | Herpetad | Herpofug Basics | Herpoviric | Juviral | Mapox | Supraviran | Virulax | Virzin | Wariviron | Zovirax</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Aciclodan | Aciclovir 1A Farma | Aciclovir alpharma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aciclor | Aciclosina | Aciclovir | Aciclovir Alfa | Aciclovir Inmenol | Aciclovir lam | Aciclovir mk | Acifur | Cicloferon | Eurovir | Eurovir forte | Fravirax | Lovir | Nor Clovir | Poviral | Simplevir | Ultravir | Virobis | Vironida | Viroter | Wariviron | Zovirax</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir mk | Aciclovir sodio | Acyvir | Alviret | Cloviril | Compaclovir | Ecuvir | Eurovir | Eurovir forte | Herpexil | Libravir | Lisovyr | Poviral | Roidil | Vironida | Zovirax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acic | Aciclovir alpharma | Aciclovir baxter | Aciclovir claris | Acyclostad | Acyclovir | Asirax | Geavir | Herpevirum | Medovir | Supraviran | Virolex | Xorox | Zovirax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Acivirax | Acyclovir | Acyclovir stada | Cycloviral | Lovir | Novirus | Virustat | Zovirax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aciclostad | Aciclovir abbot | Aciclovir alonga | Aciclovir apotex | Aciclovir aurovitas | Aciclovir bayvit | Aciclovir Bexal | Aciclovir centrum | Aciclovir combino | Aciclovir Cuvefarma | Aciclovir edigen | Aciclovir korhispa | Aciclovir mabo | Aciclovir merck | Aciclovir Normon | Aciclovir pensa pharma | Aciclovir pharmagenus | Aciclovir pliva | Aciclovir qualix | Aciclovir sandoz | Aciclovir tedec | Aciclovir vir | Cusiviral | Maynar | Virherpes | Virherpes forte | Virmen | Zovirax</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir | Acyclovir denk | Lovrak | Vivorax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir mayne | Aciclovir Ranbaxy | Aciclovir sandoz | Aclovir merckle | Acyclostad | Acyclovir alpharma | Acyrax | Geavir | Zovirax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir Actavis | Aciclovir Aguettant | Aciclovir almus | Aciclovir Alter | Aciclovir arrow | Aciclovir bgr | Aciclovir biogaran | Aciclovir cristers | Aciclovir dakota | Aciclovir eg | Aciclovir Evolugen | Aciclovir G Gam | Aciclovir g gam | Aciclovir gnr | Aciclovir hikma | Aciclovir merck | Aciclovir qualimed | Aciclovir Ranbaxy | Aciclovir ratiopharm | Aciclovir rpg | Aciclovir sandoz | Aciclovir Sandoz | Aciclovir teva | Aciclovir Zydus | Zovirax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir kent | Aciclovir sandoz | Aciclovir Sandoz | Duvimex | Ranovir | Virovir | Zovirax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir/vocate | Cargosil | Cevinolol | Cycloviran | Erpizon | Etasisen | Hagevir | Helposol | Herzkur | Zovirax</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acilax | Aclovir | Acyclovir | Acyclovir stella | Acyvir | Apo Acyclovir | Apt aciclovir | Avorax | Bf-Acyclovir | Cevinolon | Cyclovax | Entir | Euroclovir | Herax | Herperax | Mayam | Medovir | Neo antivir | Qualiclovir | Stovir | Virest | Virless | Viroclear | Virucid | Virux | Wariviron | Zevin | Zoral | Zovirax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aciklovir alpha medical | Herplex | Herplexim | Virolex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir AL | Aciclovir azevedos | Ciklovir | Herpesin | Telviran | Virokill | Virolex | Zovirax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir | Azovir | Clinovir | Clopes | Clovika | Danovir | Dumophar | Eduvir | Herax | Herpiclof | Hervirex | Inavir | Kenrovir | Lovires | Matrovir | Nevirz | Palovir | Poviral | Quavir | Scanovir | Tyrus | Viralis | Vircella | Vircovir | Virdam | Vireth | Virpes | Virtaz | Virules | Zoter | Zovirax | Zumasid | Zyclorax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Bellvirax | Zovirax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Acyclo v | Acyclovir | Supra Vir | Zovirax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aciherpin | Aciv | Acivex | Acivir | Acr v | Alovir | Axovir | Cevirin | Cutivir | Cyclopiz | Cyclovir | Herperax | Herpex | Herpiday | Herpikind | Herpovir | Herzovir | Hevir | Logivir | Lovir | Neoclovir | Ocurex | Ocuvir | Psyvir | Trikase | Trinase | Univir | Vir | Virax | Vircilon | Viromax | Zovir | Zovirax | Zoylex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aciclin | Aciclovir | Aciclovir Actavis | Aciclovir alr | Aciclovir Doc | Aciclovir eg | Aciclovir fdi | Aciclovir git | Aciclovir recordati | Aciclovir zentiva | Aciviran | Acy | Acyvir | Alovir | Amodivyr | Avix | Avyclor | Avyplus | Citivir | Cycloviran | Dravyr | Efriviral | Esavir | Fuviron | Iliaclor | Immunovir | Ipaviran | Ipsovir | Neclovir | Neviran | Riduvir | Sanavir | Voraclor | Zovirax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cycloherp | Duvimex | Herpavir | Lovira | Medovir | Noviral | Supraviran | Verpis | Virustat | Zovirax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aciclomerck | Aciclovin | Aciclovin nichiiko | Aciclovir | Aciclovir kayaku | Aciclovir Yoshindo | Acilomin | Acirovec sawai | Acirovec yoshitomi | Actidas | Actidas merck hoei | Actidas nagase | Actios honso | Actios merck hoei | Actios taiyo | Acycril | Acycril fuso | Acycril teisan | Ailax | Clovate | Natazil mitsubishi | Natazil takeshima | Pharrax | Sunacyl | Tomill | Vercusron | Vicclox | Viruhexal | Viruhexal hexal | Vizocross | Zobiatron | Zobiclobill | Zobistat choseido | Zovirax glaxosmithkline</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aciherpin | Aclovir | Acyclovir | Acyclovir denk | Alcovir | Alovir | Asvir | Azzir | Cyclovax | Cyclovir | Davir | Herperax | Herpex 800 dt | Labvir | Lovir | Provir | Simplovir | Univir | Virest | Virucid | Virux | Zealor | Zovirax</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acirovi | Acle | Acloby | Aclova | Aclovin | Acrovin | Acycan | Acycliz | Acyclo | Acyclovir | Acyco | Acyem | Acylovir | Acyrax | Acyrobin | Acyrovin | Acyve | Acyvil | Acyvir | Aias | Aks | Akvi | Alovir | Anasi | Asifol | Avimasten | Bacylo | Bacylovir | Basiclon | Chicbi | Clorac | Clovir | Covir | Crocid | Cyclo | Daehwa acyclovir | Daewon acyclovir | Erpe | Hacyvir | Hanall acyclovir | Hapice | Hapis | Hawon aciclovir | Korus acyclovir | Kukje acyclovir | Kyungdong acyclovir | Menova | Pacivir | Pharmaking acyclovir | Pharvis acyclovir | Sama Acyclovir | Samsung acyclovir | Scd Acyclovir | Union acyclovir | Vaclover | Vacrax | Vacrovir | Virax | Vivir | Wooridul acyclovir | Young poong acyclovir | Zios | Zodiac | Zovirax | Zoylex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Acic | Clovir | Lovrak | Supraviran | Virucid | Virustat | Zovirax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Acti Vir | Cyclovex | Supraviran | Wariviron | Xorox | Zovirax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acic | Aciclovir Actavis | Aciclovir baxter | Aciclovir claris | Aciclovir medochemie | Aciclovir olikla | Aviral | Citivir | Cyclovir | Herpesin | Virolex | Zovirax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir eg | Aciclovir ratiopharm | Aciclovir sandoz | Docaciclo | Supraviran | Zovirax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acic | Aciclostad | Aciclovir | Aciclovir ratiopharm | Acivir | Aviral | Cyclovir | Geavir | Herpelans | Herpesin | Herpofug | Heviran | Provirsan | Virolex | Xorox | Zovirax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aciclosine | Cicloviral | Herpevir | Revocir | Virpes | Zovirax | Zozma</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir gi | Aciclovir gi lemer | Aciclovir gi pisa | Aciclovir gi preci | Aciclovir gi serra | Aciclovir mavi | Aciclovir Raam | Aciclovir rayere | Acifur | Aveciclar | Avirex | Avirex I | Brimex | Cicloferon | Clirbest | Clociver | Clorixan | Clyvorax | Dyskly | Erser | Espen | Genovix | Isavir | Laciken | Landvir | Lesaclor | Maclov | Olsisol | Pixeven | Rivocilvar | Soviclor | Vicloran | Viclovir | Victoclir | Viremix | Virestat | Viroxil | Zirconia | Ziverone | Zovirax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Acic | Aciclovir | Acyclovir | Acyclovir sodium | Acylete | Aviral | Avorax | Cyclovax | Dravyr | Hepirax | Herpevex | Lovir | Medovir | Saforax | Vaxcel Acyclovir | Virest | Virless | Virox | Virucid | Zevin | Zirax | Zoral | Zorax | Zoraxin | Zovirax</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir | Acylex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir hikma | Aciclovir ratiopharm | Aciclovir-gf | Zovirax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir accord | Aciclovir Hospira | Aciclovir mayne | Aciclovir pfizer | Aciclovir Ranbaxy | Aciklovir gea | Acyclovir | Geavir | Zovirax</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir claris | Acyclovir | Alpha-aciclovir | Apo-aciclovir | Global acyclovir | Lovir | Zovirax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acevir | Aciclovir | Aciclovir fmndtria | Aciviclor | Cesumar | Clovimix | Clovirax | Herperax | Lovir | Trinaler | Vironida | Virusan | Zicovir | Zodylex | Zovirax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acevir | Aciclovir | Aciherpin | Acyclovir stada | Axivir | Ciclox | Clovir | Cloviron | Covelay | Cyclostad | Cyllanvir | Hapivir | Herpex | Innovirax | Klozivex | Lovir | Pharex aciclovir | Raxclo | Syclovir | Viralex | Virest | Xyclovirax | Zealor | Zovirax | Zylovir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aclova | Aclovir | Acv | Acyclovir | Acylex | Anavir | Clovir | Clovirex | Cycloz | Elovir | Herpex | Hypovir | Klovir | Mecylex | Santovir | Supraviran | Virmack | Virocil | Virq | Virucid | Virustal | Zaclovir | Zoraxin | Zovirax | Zoylex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Aciclovir aurovitas | Acix | Acyclovir stada | Antivir | Apo Acyclovir | Hascovir | Hascovir control | Hascovir control max | Herpesin | Hevipoint | Heviran | Heviran comfort | Heviran comfort max | Invirum | Ranviran | Virolex | Zovirax | Zovirax active</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir | Acyclovir sodium | Zovirax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aciclosina | Aciclovax | Aciclovir | Aciclovir Actavis | Aciclovir angenerico | Aciclovir azevedos | Cicloviral | Divicil | Faulviral | Hermix | Hermocil | Zov800 | Zovirax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aciclor | Aciclovir dallas | Aciclovir dutriec | Aciclovir empa | Aciclovir genfar | Aciclovir icu vita | Aciclovir imedic | Aciclovir kirei | Aciclovir la sante | Aciclovir lch | Aciclovir mintlab | Aciclovir natrodale | Aciclovir pharmavial | Aciclovir phi | Aciclovir polimed | Aciclovir promepar | Aciclovir prosalud | Aciclovir teuto | Aciclovir vivele | Avir | Clovir | Eliclor | Eurovir | Eurovir forte | Heclovir | Trinaler | Trinaler Forte | Vidermina | Vihrox | Vironida | Vironida forte | Vixmifin | Xiclovir | Zovirax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Acic | Acyclovir Mabo | Cilovar IV | Clovir (Spimaco) | Cycloviral | Lovir | Lovrak | Noviral | Virpes | Wariviron | Zovirax | Zovirax DS | Zovirax IV</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir arena | Aciclovir laropharm | Aciclovir richter | Aciclovir slavia | Aciclovir terapia | Aciklovir | Avyclor | Cyclovir | Euvirox | Herpesin | Herpex | Viricin | Virolex | Zovirax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aciclostad | Aciclovir | Aciclovir akos | Aciclovir belupo | Aciclovir forte | Aciclovir j | Aciclovir reneval | Aciclovir sandoz | Aciherpin | Acyclovir | Acyclovir stada | Bonafton | Citivir | Cyclovir | Cycloviral sedico | Herperax | Herpevir | Lisavyr | Medovir | Provirsan | Supraviran | Vero acyclovir | Virolex | Vivorax | Zovirax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Acyclovir | Acyclovir jpi | Apo Acyclovir | Clovir | Lovrak | Mevirox | Virustat | Zovirax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir Alpharma | Aciclovir Hospira | Aciclovir mds | Aciclovir Merck NM | Aciclovir orion | Aciclovir Ranbaxy | Aciclovir sandoz | Aciklovir Norcox | Aciklovir Ratiopharm | Aciklovir Stada | Acyclovir Actavis | Acyclovir alpharma | Geavir | Zovir | Zovirax | Zovirax Novum</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Acyclovir | Avorax | Bearax | Dravyr | Entir | Erlvirax | Herperax | Lovir | Medovir | SP-Virac | Vacrax | Vilerm | Virest | Virless | Vivorax | Zoral | Zorax | Zoraxin | Zovirax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Virolex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Herpesin | Medovir | Telviran | Virolex | Zovirax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A.c.v. | Acevax | Aciclovir | Acovax | Acyclovir abbott vial | Acyvir | Avirrex | Axovir | Azovax | Clinovir | Clovir | Clovira | Clovirax | Clovirex | Colsor | Colxor | Covir | Cyclovax | Dbl aciclovir vial | Entir | Falerm | Gynovir | Herpenon | Herperax | Herpirax | Kimvac | Lermex | Marvir | Monirax | Norum | Paviria | Pharsorex | Pipzovivir | Ranvir | Reclovax | Starclovir | Trovir | Vermis | Viclovir | Vilerm | Virax | Viraxy | Vircox | Virofik | Virogon | Viromed | Viron | Vironil | Viropox | Virorax | Virovir | Vivir | Vizo | Zevin | Zocovin | Zorax | Zova | Zovirax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir mylan | Aciclovir Opalia | Antivir | Avaltex | Mevirox | Zovirax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acyl | Aklovir | Asimplex | Asirax | Asiviral | Hernovir | Klovireks l | Klovireks L | Provir | Silovir | Virosil | Xorox | Zovirax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Acyclovir | Acylete | Acylo | Deherp | Lipaoshu | Medovir | Skirax | Vaxcel Acyclovir | Virless | Zovirax</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acic | Aciherpin | Acyclovir | Acyclovir Akri | Cyclovir | Herpesin | Herpevir | Heviran | Lipster | Lovir | Medovir | Virolex | Vivorax | Zovirax</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir denk | Agovir | Alovir | Asvir | Avir | Avorax | Cycloren | Cyclovax | Ficyc | Virest</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aciclovir | Dicipal | Expit | Poviral | Viraplex | Virulax | Zovirax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aciclor | Aciclovir | Acyclovir | Antivirax | Avir | Cloryvil | Clovirex | Herpiclor | Isavir | Klovir | Ultravir | Zovirax</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Acyacy | Agiclovir | Avirtab | Bondaxil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir accord | Acyclovir biotech | Acyrax | Adco-acyclovir | Apo Acyclovir | Cyclivex | Mylan Aciclovir | Pharmacare-acyclovir | Vyrohexal | Zovirax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Acyclex | Acyclovir | Acyclovir denk | Agovir | Ar clovir | Cyclovax | Cycloz | Herpex | Herpex 800 dt | Kamvir | Univir | Virest | Vivorax | Zovex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Acyclovir | Alovir | Apo Acyclovir | Cyclovax | Herperax | Viramed | Viratak</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-DAVA.1">
<a name="DAVA.1"></a>Acyclovir capsule, tablet [prescribing information]. Fort Lee, NJ: DAVA Pharmaceuticals, Inc; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zydus.1">
<a name="Zydus.1"></a>Acyclovir Sodium injection [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc: May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zydus.2">
<a name="Zydus.2"></a>Acyclovir Sodium injection [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc: June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GSK.1">
<a name="GSK.1"></a>Acyclovir Capsules, USP [prescribing information]. Washington, DC: Modavar Pharmaceuticals LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7973922">
<a name="7973922"></a>Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. <i>South Med J</i>. 1994;87(12):1227-1231. doi: 10.1097/00007611-199412000-00006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7973922/pubmed" id="7973922" target="_blank">7973922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8651631">
<a name="8651631"></a>Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. <i>Ann Otol Rhinol Laryngol</i>. 1996;105(5):371-378. doi: 10.1177/000348949610500508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8651631/pubmed" id="8651631" target="_blank">8651631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23772935">
<a name="23772935"></a>Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM; National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. <i>Paediatr Perinat Epidemiol</i>. 2013;27(4):340-345. doi:10.1111/ppe.12064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/23772935/pubmed" id="23772935" target="_blank">23772935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albrecht.2020a">
<a name="Albrecht.2020a"></a>Albrecht MA, Levin MJ. Treatment of herpes zoster. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albrecht.2020b">
<a name="Albrecht.2020b"></a>Albrecht MA. Treatment of varicella (chickenpox) infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7777108">
<a name="7777108"></a>Almond MK, Fan S, Dhillon S, Pollock AM, Raftery MJ. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. <i>Nephron</i>. 1995;69(4):428-432. doi:10.1159/000188514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7777108/pubmed" id="7777108" target="_blank">7777108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett E, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8382784">
<a name="8382784"></a>American Academy of Pediatrics Committee on Infectious Diseases, “The Use of Oral Acyclovir in Otherwise Healthy Children With Varicella,” <i>Pediatrics</i>, 1993, 91(3):674-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8382784/pubmed" id="8382784" target="_blank">8382784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26000539">
<a name="26000539"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. <i>Obstet Gynecol</i>. 2015;125(6):1510-1525. doi:10.1097/01.AOG.0000466430.19823.53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26000539/pubmed" id="26000539" target="_blank">26000539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32332414">
<a name="32332414"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 220: Management of genital herpes in pregnancy. <i>Obstet Gynecol</i>. 2020;135(5):e193-e202. doi:10.1097/AOG.0000000000003840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32332414/pubmed" id="32332414" target="_blank">32332414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9224082">
<a name="9224082"></a>Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. <i>BMJ</i>. 1997;314(7097):1800-1803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9224082/pubmed" id="9224082" target="_blank">9224082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32549883">
<a name="32549883"></a>Andrews AR, Yu D, Lyon AW. Diagnostic challenges with acyclovir crystalluria - a case study. <i>EJIFCC</i>. 2020;31(2):157-163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32549883/pubmed" id="32549883" target="_blank">32549883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8809466">
<a name="8809466"></a>Arvin AM. Varicella-zoster virus. <i>Clin Microbiol Rev.</i> 1996;9(3):361-381. doi:10.1128/CMR.9.3.361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8809466/pubmed" id="8809466" target="_blank">8809466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10210711">
<a name="10210711"></a>Balfour HH Jr. Antiviral drugs. <i>N Engl J Med</i>. 1999;340(16):1255-1268. doi: 10.1056/NEJM199904223401608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10210711/pubmed" id="10210711" target="_blank">10210711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6343861">
<a name="6343861"></a>Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. <i>N Engl J Med</i>. 1983;308(24):1448-1453. doi:10.1056/NEJM198306163082404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/6343861/pubmed" id="6343861" target="_blank">6343861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31024972">
<a name="31024972"></a>Barber KE, Wagner JL, Stover KR. Impact of obesity on acyclovir-induced nephrotoxicity. <i>Open Forum Infect Dis</i>. 2019;6(4):ofz121. doi:10.1093/ofid/ofz121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31024972/pubmed" id="31024972" target="_blank">31024972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24189771">
<a name="24189771"></a>Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. <i>Otolaryngol Head Neck Surg</i>. 2013;149(3)(suppl):S1-S27. doi:10.1177/0194599813505967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24189771/pubmed" id="24189771" target="_blank">24189771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8190194">
<a name="8190194"></a>Beales P, Almond MK, Kwan JT. Acyclovir neurotoxicity following oral therapy: prevention and treatment in patients on haemodialysis. <i>Nephron</i>. 1994;66(3):362-363. doi:10.1159/000187841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8190194/pubmed" id="8190194" target="_blank">8190194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9352739">
<a name="9352739"></a>Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). <i>Medicine (Baltimore)</i>. 1997;76(5):369-380. doi: 10.1097/00005792-199709000-00004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9352739/pubmed" id="9352739" target="_blank">9352739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794437">
<a name="31794437"></a>Bełz A, Dębowska P, Głogowska-Szeląg J. Acyclovir neurotoxicity in an elderly patient with end-stage renal failure. <i>Am J Ther</i>. 2020;27(5):e525-e527. doi:10.1097/MJT.0000000000001012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31794437/pubmed" id="31794437" target="_blank">31794437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7767151">
<a name="7767151"></a>Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. <i>BMJ</i>. 1995;310(6988):1169-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7767151/pubmed" id="7767151" target="_blank">7767151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25440915">
<a name="25440915"></a>Berry L, Venkatesan P. Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis. <i>J Clin Virol</i>. 2014;61(4):608-610. doi: 10.1016/j.jcv.2014.09.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/25440915/pubmed" id="25440915" target="_blank">25440915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7048911">
<a name="7048911"></a>Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. <i>Am J Med</i>. 1982;73(1A):186-192. doi:10.1016/0002-9343(82)90088-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7048911/pubmed" id="7048911" target="_blank">7048911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31263790">
<a name="31263790"></a>Blumental S, Lepage P. Management of varicella in neonates and infants. <i>BMJ Paediatr Open</i>. 2019;3(1):e000433. doi:10.1136/bmjpo-2019-000433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31263790/pubmed" id="31263790" target="_blank">31263790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282339">
<a name="16282339"></a>Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. <i>Blood</i>. 2006;107(5):1800-1805. doi: 10.1182/blood-2005-09-3624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/16282339/pubmed" id="16282339" target="_blank">16282339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19299333">
<a name="19299333"></a>Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. <i>Blood</i>. 2009;113(23):5711-5719. doi: 10.1182/blood-2008-10-143560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/19299333/pubmed" id="19299333" target="_blank">19299333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3624115">
<a name="3624115"></a>Boelaert J, Schurgers M, Daneels R, Van Landuyt HW, Weatherley BC. Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. <i>J Antimicrob Chemother</i>. 1987;20(1):69-76. doi:10.1093/jac/20.1.69<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/3624115/pubmed" id="3624115" target="_blank">3624115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonis.2020">
<a name="Bonis.2020"></a>Bonis PA, Kotton CN. Herpes simplex virus infection of the esophagus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7751454">
<a name="7751454"></a>Bork K, Benes P. Concentration and kinetic studies of intravenous acyclovir in serum and breast milk of a patient with eczema herpeticum. <i>J Am Acad Dermatol</i>. 1995;32(6):1053-1055.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7751454/pubmed" id="7751454" target="_blank">7751454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32360486">
<a name="32360486"></a>Boujenah J, Cohen E, Carbillon L. Intravenous acyclovir-induced nephrotoxicity. Is pregnancy a risk factor? <i>J Gynecol Obstet Hum Reprod</i>. 2020;49(8):101783. doi:10.1016/j.jogoh.2020.101783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32360486/pubmed" id="32360486" target="_blank">32360486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9421114">
<a name="9421114"></a>Boulieu R, Bastien O, Gaillard S, Flamens C. Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. <i>Ther Drug Monit</i>. 1997;19(6):701-704. doi:10.1097/00007691-199712000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9421114/pubmed" id="9421114" target="_blank">9421114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022: 97-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34146428">
<a name="34146428"></a>Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, Martín Herranz I. Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases. <i>J Clin Pharm The</i>r. 2021;46(4):918-926. doi:10.1111/jcpt.13464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/34146428/pubmed" id="34146428" target="_blank">34146428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9532986">
<a name="9532986"></a>Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. <i>Br J Obstet Gynaecol</i>. 1998;105(3):275-280. doi:10.1111/j.1471-0528.1998.tb10086.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9532986/pubmed" id="9532986" target="_blank">9532986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32550073">
<a name="32550073"></a>Bukhari S, Aslam HM, Awwal TA, Christmas D, Wallach SL. Valacyclovir-induced thrombotic thrombocytopenic purpura. <i>Cureus</i>. 2020;12(5):e8156. doi: 10.7759/cureus.8156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32550073/pubmed" id="32550073" target="_blank">32550073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20616659">
<a name="20616659"></a>Canalejo E, García Durán F, Cabello N, García Martínez J. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2010;89(4):204-210. doi: 10.1097/MD.0b013e3181e949ed.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20616659/pubmed" id="20616659" target="_blank">20616659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21160459">
<a name="21160459"></a>Centers for Disease Control and Prevention (CDC), "Sexually Transmitted Diseases Treatment Guidelines, 2010," <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/21160459/pubmed" id="21160459" target="_blank">21160459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541820">
<a name="18541820"></a>Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. <i>Arch Intern Med</i>. 2008;168(11):1137-1144. doi: 10.1001/archinte.168.11.1137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/18541820/pubmed" id="18541820" target="_blank">18541820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26769041">
<a name="26769041"></a>Chamizo FJ, Gilarranz R, Hernández M, Ramos D, Pena MJ. Central nervous system infections caused by varicella-zoster virus. <i>J Neurovirol</i>. 2016;22(4):529-532. doi: 10.1007/s13365-016-0422-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26769041/pubmed" id="26769041" target="_blank">26769041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30428841">
<a name="30428841"></a>Chávez-Iñiguez JS, Medina-Gonzalez R, Aguilar-Parra L, et al. Oral acyclovir induced hypokalemia and acute tubular necrosis a case report. <i>BMC Nephrol</i>. 2018;19(1):324. doi: 10.1186/s12882-018-1121-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30428841/pubmed" id="30428841" target="_blank">30428841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24942005">
<a name="24942005"></a>Chowdhury MA, Derar N, Hasan S, Hinch B, Ratnam S, Assaly R. Acyclovir-induced neurotoxicity: a case report and review of literature. <i>Am J Ther</i>. 2016;23(3):e941-e943. doi: 10.1097/MJT.0000000000000093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24942005/pubmed" id="24942005" target="_blank">24942005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375341">
<a name="10375341"></a>Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. <i>Ann Intern Med</i>. 1999;130(11):922-932. doi:10.7326/0003-4819-130-11-199906010-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10375341/pubmed" id="10375341" target="_blank">10375341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840531">
<a name="30840531"></a>D'Andrea MA, Spatz DL. Maintaining breastfeeding during severe infant and maternal HSV-1 infection: a case report. <i>J Hum Lact</i>. 2019;35(4):737-741. doi:10.1177/0890334419830994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30840531/pubmed" id="30840531" target="_blank">30840531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1462997">
<a name="1462997"></a>Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. <i>Am J Kidney Dis</i>. 1992;20(6):647-649. doi:10.1016/s0272-6386(12)70234-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/1462997/pubmed" id="1462997" target="_blank">1462997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24934895">
<a name="24934895"></a>de Almeida JR, Guyatt GH, Sud S, et al; Bell Palsy Working Group, Canadian Society of Otolaryngology - Head and Neck Surgery and Canadian Neurological Sciences Federation. Management of Bell palsy: clinical practice guideline. <i>CMAJ. </i>2014;186(12):917-922. doi: 10.1503/cmaj.131801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24934895/pubmed" id="24934895" target="_blank">24934895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6355048">
<a name="6355048"></a>de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. <i>J Antimicrob Chemother</i>. 1983;12(suppl B):29-37. doi:10.1093/jac/12.suppl_b.29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/6355048/pubmed" id="6355048" target="_blank">6355048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32807089">
<a name="32807089"></a>Diezma-Martín AM, Gigante-Miravalles E, Castro Limo JD, Quimbayo Arcila CA, Puche Paniagua JJ. Herpetic esophagitis in immunocompentent host: cases report. <i>BMC Infect Dis</i>. 2020;20(1):605. doi:10.1186/s12879-020-05328-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32807089/pubmed" id="32807089" target="_blank">32807089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32037154">
<a name="32037154"></a>Downes KJ, Boge CLK, Baro E, et al. Acute kidney injury during treatment with intravenous acyclovir for suspected or confirmed neonatal herpes simplex virus infection. <i>J Pediatr</i>. 2020;219:126-132.e2. doi:10.1016/j.jpeds.2019.12.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32037154/pubmed" id="32037154" target="_blank">32037154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17143845">
<a name="17143845"></a>Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. <i>Clin Infect Dis</i>. 2007;44(suppl 1):S1-S26. doi:10.1086/510206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/17143845/pubmed" id="17143845" target="_blank">17143845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2066845">
<a name="2066845"></a>Englund JA, Fletcher CV, and Balfour HH Jr, “Acyclovir Therapy in Neonates,” <i>J Pediatr</i>, 1991, 119(1 Pt 1):129-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/2066845/pubmed" id="2066845" target="_blank">2066845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8645798">
<a name="8645798"></a>Fazal BA, Turett GS, Justman JE, Hall G, Telzak EE. Stevens-Johnson syndrome induced by treatment with acyclovir. <i>Clin Infect Dis</i>. 1995;21(4):1038-1039. doi: 10.1093/clinids/21.4.1038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8645798/pubmed" id="8645798" target="_blank">8645798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9419169">
<a name="9419169"></a>Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. <i>J Infect Dis</i>. 1998;177(1):48-56. doi: 10.1086/513804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9419169/pubmed" id="9419169" target="_blank">9419169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.2020">
<a name="Fishman.2020"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20862348">
<a name="20862348"></a>Fleischer R, Johnson M. Acyclovir nephrotoxicity: a case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy. <i>Case Rep Med</i>. 2010;2010:602783. doi: 10.1155/2010/602783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20862348/pubmed" id="20862348" target="_blank">20862348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21205990">
<a name="21205990"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/21205990/pubmed" id="21205990" target="_blank">21205990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1847004">
<a name="1847004"></a>Frenkel LM, Brown ZA, Bryson YJ, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. <i>Am J Obstet Gynecol</i>. 1991;164(2):569-576. doi:10.1016/s0002-9378(11)80023-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/1847004/pubmed" id="1847004" target="_blank">1847004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31486071">
<a name="31486071"></a>Gagyor I, Madhok VB, Daly F, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD001869. doi:10.1002/14651858.CD001869.pub9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31486071/pubmed" id="31486071" target="_blank">31486071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356666">
<a name="28356666"></a>Goli R, Mukku KK, Devaraju SB, Uppin MS. Acyclovir-induced thrombotic microangiopathy. <i>Indian J Nephrol</i>. 2017;27(2):131-132. doi: 10.4103/0971-4065.181453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/28356666/pubmed" id="28356666" target="_blank">28356666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. </i>New York, NY: Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28067468">
<a name="28067468"></a>Gorlitsky BR, Herion JT. Sticking to the script: A curious case of confusion in an ESRD patient. <i>Hemodial Int</i>. 2017;21(3):E58-E62. doi: 10.1111/hdi.12534.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/28067468/pubmed" id="28067468" target="_blank">28067468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23136264">
<a name="23136264"></a>Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(22):2209-2213. doi: 10.1212/WNL.0b013e318275978c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/23136264/pubmed" id="23136264" target="_blank">23136264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22005269">
<a name="22005269"></a>Gunness P, Aleksa K, Bend J, Koren G. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. <i>Transl Res</i>. 2011;158(5):290-301. doi: 10.1016/j.trsl.2011.07.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/22005269/pubmed" id="22005269" target="_blank">22005269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15889353">
<a name="15889353"></a>Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2005;40(11):1559-1585. doi: 10.1086/430257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/15889353/pubmed" id="15889353" target="_blank">15889353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22345887">
<a name="22345887"></a>Gurkan A, Erkek N, Senel S. Localized bullous eruptions away from infusion site due to intravenous acyclovir administration in a child. <i>Indian J Pharmacol</i>. 2012;44(1):126-128. doi: 10.4103/0253-7613.91885.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/22345887/pubmed" id="22345887" target="_blank">22345887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8430717">
<a name="8430717"></a>Haefeli WE, Schoenenberger RA, Weiss P, Ritz RF. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. <i>Am J Med</i>. 1993;94(2):212-215. doi: 10.1016/0002-9343(93)90186-s.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8430717/pubmed" id="8430717" target="_blank">8430717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16540518">
<a name="16540518"></a>Helldén A, Lycke J, Vander T, Svensson JO, Odar-Cederlöf I, Ståhle L. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.<i> J Antimicrob Chemother</i>. 2006;57(5):945-949. doi: 10.1093/jac/dkl067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/16540518/pubmed" id="16540518" target="_blank">16540518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1453110">
<a name="1453110"></a>Henderson GI, Hu ZQ, Johnson RF, Perez AB, Yang Y, Schenker S. Acyclovir transport by the human placenta. <i>J Lab Clin Med</i>. 1992;120(6):885-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/1453110/pubmed" id="1453110" target="_blank">1453110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31122930">
<a name="31122930"></a>Holland C, Sadarangani M. Fifteen-minute consultation: Prevention and treatment of chickenpox in newborns. <i>Arch Dis Child Educ Pract Ed</i>. 2020;105(1):24-30. doi:10.1136/archdischild-2018-316715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31122930/pubmed" id="31122930" target="_blank">31122930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24368610">
<a name="24368610"></a>Hoskote SS, Annapureddy N, Ramesh AK, Rose K, Jones JP. Valacyclovir and acyclovir neurotoxicity with status epilepticus. <i>Am J Ther</i>. 2016;23(1):e304-e306. doi: 10.1097/MJT.0000000000000003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24368610/pubmed" id="24368610" target="_blank">24368610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577329">
<a name="17577329"></a>Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. <i>Oral Dis</i>. 2007;13(4):414-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/17577329/pubmed" id="17577329" target="_blank">17577329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi: 10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22095814">
<a name="22095814"></a>Jen SP, Sharma R, Kochar S. Probable acyclovir-induced angioedema in a patient with HIV infection and suspected varicella-zoster virus encephalitis. <i>Am J Health Syst Pharm</i>. 2011;68(23):2257-2260. doi: 10.2146/ajhp100639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/22095814/pubmed" id="22095814" target="_blank">22095814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27195158">
<a name="27195158"></a>Kadayakkara DK, Candelaria A, Kwak YE, Loeser C. Herpes simplex virus-2 esophagitis in a young immunocompetent adult. <i>Case Rep Gastrointest Med</i>. 2016;2016:7603484. doi:10.1155/2016/7603484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/27195158/pubmed" id="27195158" target="_blank">27195158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9790357">
<a name="9790357"></a>Kimberlin DF, Weller S, Whitley RJ, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. <i>Am J Obstet Gynecol</i>. 1998;179(4):846-851. doi:10.1016/s0002-9378(98)70176-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9790357/pubmed" id="9790357" target="_blank">9790357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21991950">
<a name="21991950"></a>Kimberlin DW, Whitley RJ, Wan W, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oral acyclovir suppression and neurodevelopment after neonatal herpes. <i>N Engl J Med</i>. 2011;365(14):1284-1292. doi: 10.1056/NEJMoa1003509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/21991950/pubmed" id="21991950" target="_blank">21991950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483782">
<a name="11483782"></a>Kimberlin DW, Lin CY, Jacobs RF, et al, “Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections,” <i>Pediatrics</i>, 2001, 108(2):230-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/11483782/pubmed" id="11483782" target="_blank">11483782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359576">
<a name="23359576"></a>Kimberlin DW, Baley J; Committee on Infectious Diseases; Committee on Fetus and Newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. <i>Pediatrics</i>. 2013;131(2):e635-e646. doi: 10.1542/peds.2012-3216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/23359576/pubmed" id="23359576" target="_blank">23359576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26831480">
<a name="26831480"></a>Kubin ME, Jackson P, Riekki R. Acute generalized exanthematous pustulosis secondary to acyclovir confirmed by positive patch testing. <i>Acta Derm Venereol</i>. 2016;96(6):860-861. doi: 10.2340/00015555-2352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26831480/pubmed" id="26831480" target="_blank">26831480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33748051">
<a name="33748051"></a>Lai JW, Ford T, Cherian S, Campbell AJ, Blyth CC. Case report: neonatal varicella acquired from maternal zoster. <i>Front Pediatr</i>. 2021;9:649775. doi:10.3389/fped.2021.649775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/33748051/pubmed" id="33748051" target="_blank">33748051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23312723">
<a name="23312723"></a>Lam NN, Weir MA, Yao Z, et al. Risk of acute kidney injury from oral acyclovir: a population-based study. <i>Am J Kidney Dis</i>. 2013;61(5):723-729. doi: 10.1053/j.ajkd.2012.12.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/23312723/pubmed" id="23312723" target="_blank">23312723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6342900">
<a name="6342900"></a>Laskin OL. Clinical pharmacokinetics of acyclovir. <i>Clin Pharmacokinet</i>. 1983;8(3):187-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/6342900/pubmed" id="6342900" target="_blank">6342900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7103443">
<a name="7103443"></a>Laskin OL, Longstreth JA, Saral R, de Miranda P, Keeney R, Lietman PS. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. <i>Antimicrob Agents Chemother</i>. 1982;21(3):393-398. doi:10.1128/aac.21.3.393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7103443/pubmed" id="7103443" target="_blank">7103443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3808527">
<a name="3808527"></a>Lau RJ, Emery MG, Galinsky RE. Unexpected accumulation of acyclovir in breast milk with estimation of infant exposure. <i>Obstet Gynecol</i>. 1987;69(3, pt 2):468-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/3808527/pubmed" id="3808527" target="_blank">3808527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30741619">
<a name="30741619"></a>Lee EJ, Jang HN, Cho HS, et al. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. <i>Ren Fail</i>. 2018;40(1):687-692. doi: 10.1080/0886022X.2018.1487866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30741619/pubmed" id="30741619" target="_blank">30741619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26369523">
<a name="26369523"></a>Lee HJ, Kim JM, Kim GW, et al. Fixed drug eruption due to acyclovir, valacyclovir and famciclovir. <i>J Eur Acad Dermatol Venereol</i>. 2016;30(8):1417-1419. doi: 10.1111/jdv.13261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26369523/pubmed" id="26369523" target="_blank">26369523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859647">
<a name="30859647"></a>Lee DH, Zuckerman RA; AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13526. doi:10.1111/ctr.13526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30859647/pubmed" id="30859647" target="_blank">30859647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10945375">
<a name="10945375"></a>Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. <i>Drug Saf</i>. 2000;23(2):131-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10945375/pubmed" id="10945375" target="_blank">10945375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20085679">
<a name="20085679"></a>Leung DT, Henning PA, Wagner EC, et al. Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. <i>J Obstet Gynaecol Can</i>. 2009;31(12):1137-1143. doi:10.1016/s1701-2163(16)34374-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20085679/pubmed" id="20085679" target="_blank">20085679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929799">
<a name="11929799"></a>Ljungman P, de La Camara R, Milpied N, et al; Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. <i>Blood</i>. 2002;99(8):3050-3056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/11929799/pubmed" id="11929799" target="_blank">11929799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31504577">
<a name="31504577"></a>Lindström J, Helldén A, Lycke J, Grahn A, Studahl M. An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study. <i>J Antimicrob Chemother</i>. 2019;74(12):3565-3572. doi: 10.1093/jac/dkz357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31504577/pubmed" id="31504577" target="_blank">31504577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7614161">
<a name="7614161"></a>MacPhail L, Greenspan D. Herpetic gingivostomatitis in a 70-year-old man. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod.</i> 1995;79(1):50-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7614161/pubmed" id="7614161" target="_blank">7614161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32850129">
<a name="32850129"></a>Marks D, De La Paz A, Walston BJ. Acyclovir-induced neurotoxicity in an immunocompromised patient. <i>SAGE Open Med Case Rep</i>. 2020;8:2050313X20946518. doi:10.1177/2050313X20946518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32850129/pubmed" id="32850129" target="_blank">32850129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081790">
<a name="31081790"></a>Martinot M, Klein A, Demesmay K, et al. Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis. <i>Antivir Ther</i>. 2019;24(4):309-312. doi:10.3851/IMP3313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31081790/pubmed" id="31081790" target="_blank">31081790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25215030">
<a name="25215030"></a>Meng JB, Zheng X, Zhang G, Fang Q. Oral acyclovir induced acute renal failure. <i>World J Emerg Med</i>. 2011;2(4):310-313. doi: 10.5847/wjem.j.1920-8642.2011.04.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/25215030/pubmed" id="25215030" target="_blank">25215030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12192020">
<a name="12192020"></a>Moake JL. Thrombotic microangiopathies. <i>N Engl J Med</i>. 2002;347(8):589-600. doi: 10.1056/NEJMra020528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/12192020/pubmed" id="12192020" target="_blank">12192020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21208452">
<a name="21208452"></a>Numthavaj P, Thakkinstian A, Dejthevaporn C, Attia J. Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis. <i>BMC Neurol</i>. 2011;11:1. doi:10.1186/1471-2377-11-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/21208452/pubmed" id="21208452" target="_blank">21208452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9514106">
<a name="9514106"></a>Ogilvie MM, "Antiviral Prophylaxis and Treatment in Chickenpox. A Review Prepared for the UK Advisory Group on Chickenpox on Behalf of the British Society for the Study of Infection," <i>J Infect</i>, 1998, 36(Suppl 10):31-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9514106/pubmed" id="9514106" target="_blank">9514106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727504">
<a name="20727504"></a>Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. <i>Adv Chronic Kidney Dis</i>. 2010;17(5):e53-e62. doi:10.1053/j.ackd.2010.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20727504/pubmed" id="20727504" target="_blank">20727504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34713692">
<a name="34713692"></a>Paluch Z, Trojánek M, Velíšková Z, et al. Neurotoxic side effects of acyclovir: two case reports. <i>Neuro Endocrinol Lett</i>. 2021;42(6):375-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/34713692/pubmed" id="34713692" target="_blank">34713692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33658895">
<a name="33658895"></a>Pańczyk-Tomaszewska M, Kuźma-Mroczkowska E, Skrzypczyk P, Szymanik-Grzelak H, Małdyk J. Acute tubulointerstitial nephritis following aciclovir treatment for chickenpox in children with nephrotic syndrome - a report of two cases. <i>Cent Eur J Immunol</i>. 2020;45(4):494-497. doi:10.5114/ceji.2020.103426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/33658895/pubmed" id="33658895" target="_blank">33658895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736469">
<a name="20736469"></a>Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. <i>JAMA</i>. 2010;304(8):859-866. doi:10.1001/jama.2010.1206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20736469/pubmed" id="20736469" target="_blank">20736469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31171414">
<a name="31171414"></a>Patel J, Hayes B, Bauler L, Mastenbrook J. Neurologic acyclovir toxicity in the absence of kidney injury. <i>J Emerg Med</i>. 2019;57(2):e35-e39. doi: 10.1016/j.jemermed.2019.03.050.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31171414/pubmed" id="31171414" target="_blank">31171414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10225250">
<a name="10225250"></a>Perazella MA. Crystal-induced acute renal failure. <i>Am J Med</i>. 1999;106(4):459-465. doi: 10.1016/s0002-9343(99)00041-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10225250/pubmed" id="10225250" target="_blank">10225250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31162727">
<a name="31162727"></a>Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13622. doi:10.1111/ctr.13622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/31162727/pubmed" id="31162727" target="_blank">31162727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Permar.1">
<a name="Permar.1"></a>Permar SR. Viral infections. In: Eichenwald EC. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017:chap. 48.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746903">
<a name="29746903"></a>Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. <i>Int J Infect Dis</i>. 2018;72:11-15. doi: 10.1016/j.ijid.2018.04.4324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/29746903/pubmed" id="29746903" target="_blank">29746903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9474615">
<a name="9474615"></a>Raborn GW, Martel AY, Grace MG, McGaw WT. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 1998;85(1):55-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/9474615/pubmed" id="9474615" target="_blank">9474615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22668620">
<a name="22668620"></a>Rahimi H, Mara T, Costella J, Speechley M, Bohay R. Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systematic review and meta-analysis. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>. 2012;113(5):618-627. doi: 10.1016/j.oooo.2011.10.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/22668620/pubmed" id="22668620" target="_blank">22668620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34841008">
<a name="34841008"></a>Rajasekaran V, Rahaman V, Hou X, Steele RW. HSV esophagitis in an immunocompetent 17-year-old. <i>Glob Pediatr Health</i>. 2021;8:2333794X211052914. doi:10.1177/2333794X211052914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/34841008/pubmed" id="34841008" target="_blank">34841008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25708691">
<a name="25708691"></a>Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. <i>J Pediatr</i>. 2015;166(6):1462‐8.e84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/25708691/pubmed" id="25708691" target="_blank">25708691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2080005">
<a name="2080005"></a>Rashed A, Azadeh B, Abu Romeh SH. Acyclovir-induced acute tubulo-interstitial nephritis. <i>Nephron</i>. 1990;56(4):436-438. doi: 10.1159/000186190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/2080005/pubmed" id="2080005" target="_blank">2080005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8228796">
<a name="8228796"></a>Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM. Distinguishing acyclovir neurotoxicity from encephalomyelitis. <i>J Intern Med</i>. 1993;234(5):507-511. doi: 10.1111/j.1365-2796.1993.tb00785.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8228796/pubmed" id="8228796" target="_blank">8228796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30083888">
<a name="30083888"></a>Richelsen RKB, Jensen SB, Nielsen H. Incidence and predictors of intravenous acyclovir-induced nephrotoxicity. <i>Eur J Clin Microbiol Infect Dis</i>. 2018;37(10):1965-1971. doi: 10.1007/s10096-018-3332-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30083888/pubmed" id="30083888" target="_blank">30083888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riley.2020">
<a name="Riley.2020"></a>Riley LE, Wald A. Genital herpes simplex virus infection and pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10847274">
<a name="10847274"></a>Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. <i>Arch Intern Med</i>. 2000;160(11):1705-1706. doi: 10.1001/archinte.160.11.1705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10847274/pubmed" id="10847274" target="_blank">10847274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32943113">
<a name="32943113"></a>Robertson KM, Harvey CL, Cunningham JM. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. <i>J Med Case Rep</i>. 2020;14(1):156. doi:10.1186/s13256-020-02498-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32943113/pubmed" id="32943113" target="_blank">32943113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10416721">
<a name="10416721"></a>Rodriguez-Serna M, Velasco M, Miquel J, de la Cuadra J, Aliaga A. Photoallergic contact dermatitis from Zovirax cream. <i>Contact Dermatitis</i>. 1999;41(1):54-55. doi: 10.1111/j.1600-0536.1999.tb06220.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/10416721/pubmed" id="10416721" target="_blank">10416721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ronthal.1">
<a name="Ronthal.1"></a>Ronthal M. Bell’s palsy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8380540">
<a name="8380540"></a>Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. a double-blind, placebo-controlled trial. <i>Ann Intern Med.</i> 1993;118(4):268-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8380540/pubmed" id="8380540" target="_blank">8380540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24346595">
<a name="24346595"></a>Sampson MR, Bloom BT, Lenfestey RW, et al. Population pharmacokinetics of intravenous acyclovir in preterm and term infants. <i>Pediatr Infect Dis J</i>. 2014;33(1):42‐49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24346595/pubmed" id="24346595" target="_blank">24346595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32404442">
<a name="32404442"></a>Sandery BJ, Erlich JH, Kennedy SE. Acute kidney injury following intravenous acyclovir in children. <i>Arch Dis Child</i>. 2020;105(12):1215-1219. doi:10.1136/archdischild-2019-317990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32404442/pubmed" id="32404442" target="_blank">32404442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17180380">
<a name="17180380"></a>Sauerbrei A and Wutzler P, "Herpes Simplex and Varicella-Zoster Virus Infections During Pregnancy: Current Concepts of Prevention, Diagnosis and Therapy. Part 2: Varicella-Zoster Virus Infections," <i>Med Microbiol Immunol</i>, 2007, 196(2):95-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/17180380/pubmed" id="17180380" target="_blank">17180380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32847898">
<a name="32847898"></a>Sen SS, Sil A, Chakraborty U, Chandra A. Stevens-Johnson syndrome-toxic epidermal necrolysis: a fatal cutaneous adverse reaction to oral acyclovir. <i>BMJ Case Rep</i>. 2020;13(8):e238555. doi:10.1136/bcr-2020-238555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/32847898/pubmed" id="32847898" target="_blank">32847898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15018852">
<a name="15018852"></a>Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. <i>J Clin Virol</i>. 2004;29(4):248-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/15018852/pubmed" id="15018852" target="_blank">15018852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24669156">
<a name="24669156"></a>Sharma A, Mohan K, Sharma R, Nirankari VS. Alopecia following oral acyclovir for the treatment of herpes simplex keratitis. <i>Middle East Afr J Ophthalmol</i>. 2014;21(1):95-7. doi: 10.4103/0974-9233.124131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24669156/pubmed" id="24669156" target="_blank">24669156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19097954">
<a name="19097954"></a>Smith CK and Arvin AM, "Varicella in the Fetus and Newborn," <i>Semin Fetal Neonatal Med</i>, 2009, 14(4):209-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/19097954/pubmed" id="19097954" target="_blank">19097954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14606623">
<a name="14606623"></a>Sodhi PK, Ratan SK. A case of chronic renal dysfunction following treatment with oral acyclovir. <i>Scand J Infect Dis</i>. 2003;35(10):770-772. doi: 10.1080/00365540310016574-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/14606623/pubmed" id="14606623" target="_blank">14606623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7247383">
<a name="7247383"></a>Spector SA, Connor JD, Hintz M, Quinn RP, Blum MR, Keeney RE. Single-dose pharmacokinetics of acyclovir. <i>Antimicrob Agents Chemother</i>. 1981;19(4):608-612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/7247383/pubmed" id="7247383" target="_blank">7247383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3411740">
<a name="3411740"></a>Spruance SL, Hamill ML, Hoge WS, Davis LG, Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. <i>JAMA</i>. 1988;260(11):1597-1599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/3411740/pubmed" id="3411740" target="_blank">3411740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2153735">
<a name="2153735"></a>Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. <i>J Infect Dis</i>. 1990;161(2):185-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/2153735/pubmed" id="2153735" target="_blank">2153735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8893152">
<a name="8893152"></a>Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. <i>Nephron</i>. 1996;74(2):337-341. doi:10.1159/000189332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8893152/pubmed" id="8893152" target="_blank">8893152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15108247">
<a name="15108247"></a>Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. <i>Birth Defects Res A Clin Mol Teratol</i>. 2004;70(4):201-207. doi:10.1002/bdra.20013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/15108247/pubmed" id="15108247" target="_blank">15108247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17942873">
<a name="17942873"></a>Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. <i>N Engl J Med</i>. 2007;357(16):1598-1607. doi:10.1056/NEJMoa072006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/17942873/pubmed" id="17942873" target="_blank">17942873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8068994">
<a name="8068994"></a>Taddio A, Klein J, Koren G. Acyclovir excretion in human breast milk. <i>Ann Pharmacother</i>. 1994;28(5):585-587. doi: 10.1177/106002809402800506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8068994/pubmed" id="8068994" target="_blank">8068994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28536235">
<a name="28536235"></a>Thind GS, Roach R. A case of acyclovir neurotoxicity presenting with atypical cerebrospinal fluid findings. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220372. doi: 10.1136/bcr-2017-220372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/28536235/pubmed" id="28536235" target="_blank">28536235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15605069">
<a name="15605069"></a>Tiffany KF, Benjamin DK Jr, Palasanthiran P, et al. Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. <i>J Perinatol</i>. 2005;25(3):156-161.doi:10.1038/sj.jp.7211247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/15605069/pubmed" id="15605069" target="_blank">15605069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24237985">
<a name="24237985"></a>Trachtman H. HUS and TTP in children. <i>Pediatr Clin North Am</i>. 2013;60(6):1513-1526. doi: 10.1016/j.pcl.2013.08.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/24237985/pubmed" id="24237985" target="_blank">24237985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al, "Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy," <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582201">
<a name="18582201"></a>Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327. doi:10.1086/589747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/18582201/pubmed" id="18582201" target="_blank">18582201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26824940">
<a name="26824940"></a>Turner RB, Cumpston A, Sweet M, et al. Prospective, controlled study of acyclovir pharmacokinetics in obese patients. <i>Antimicrob Agents Chemother</i>. 2016;60(3):1830-3. doi:10.1128/AAC.02010-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26824940/pubmed" id="26824940" target="_blank">26824940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30669921">
<a name="30669921"></a>Umoru GO, Shah PJ, Tariq F. A case report of neurotoxicity after prolonged doses of acyclovir in a patient with renal dysfunction. <i>J Pharm Pract</i>. 2020;33(2):217-221. doi:10.1177/0897190018825033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/30669921/pubmed" id="30669921" target="_blank">30669921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34729190">
<a name="34729190"></a>Upadhaya Regmi B, Subedi RC, Mandal SK, Kunwar S, Karki B. Herpes simplex esophagitis in an immunocompetent host: a case report. <i>Oxf Med Case Reports</i>. 2021;2021(10):omab091. doi:10.1093/omcr/omab091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/34729190/pubmed" id="34729190" target="_blank">34729190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2023">
<a name="HHS.2023"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated September 25, 2023. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated February 11, 2020. Accessed April 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12799156">
<a name="12799156"></a>Vander T, Medvedovsky M, Herishanu Y. Encephalopathy induced by oral acyclovir in a patient with normal renal function. <i>J Infect</i>. 2003;46(4):286. doi: 10.1053/jinf.2002.1119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/12799156/pubmed" id="12799156" target="_blank">12799156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14678212">
<a name="14678212"></a>Vernassiere C, Barbaud A, Trechot PH, Weber-Muller F, Schmutz JL. Systemic acyclovir reaction subsequent to acyclovir contact allergy: which systemic antiviral drug should then be used? <i>Contact Dermatitis</i>. 2003;49(3):155-157. doi: 10.1111/j.0105-1873.2003.00199.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/14678212/pubmed" id="14678212" target="_blank">14678212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36601749">
<a name="36601749"></a>Vonberg FW, Dawson A, Scott G, Davies N. Aciclovir-induced neurotoxicity. <i>Pract Neurol</i>. 2023;23(2):157-159. doi:10.1136/pn-2022-003597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/36601749/pubmed" id="36601749" target="_blank">36601749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1323943">
<a name="1323943"></a>Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. <i>Ann Intern Med</i>. 1992;117(5):358-363. doi:10.7326/0003-4819-117-5-358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/1323943/pubmed" id="1323943" target="_blank">1323943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22341538">
<a name="22341538"></a>Whitley RJ. The use of antiviral drugs during the neonatal period. <i>Clin Perinatol</i>. 2012;39(1):69-81. doi:10.1016/j.clp.2011.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/22341538/pubmed" id="22341538" target="_blank">22341538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1538151">
<a name="1538151"></a>Whitley RJ, Gnann JW Jr, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. <i>J Infect Dis</i>. 1992;165(3):450-455. doi:10.1093/infdis/165.3.450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/1538151/pubmed" id="1538151" target="_blank">1538151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465005">
<a name="23465005"></a>Wilck MB, Zuckerman RA; AST Infectious Diseases Community of Practice. Herpes simplex virus in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(suppl 4):121-127. doi: 10.1111/ajt.12105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/23465005/pubmed" id="23465005" target="_blank">23465005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.2018">
<a name="Wingard.2018"></a>Wingard JR. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27067742">
<a name="27067742"></a>Wong A, Pickering AJ, Potoski BA. Dosing practices of intravenous acyclovir for herpes encephalitis in obesity: results of a pharmacist survey. <i>J Pharm Pract</i>. 2017;30(3):324-328. doi: 10.1177/0897190016642689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/27067742/pubmed" id="27067742" target="_blank">27067742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8114860">
<a name="8114860"></a>Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. <i>N Engl J Med</i>. 1994;330(13):896-900. doi: 10.1056/NEJM199403313301304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/8114860/pubmed" id="8114860" target="_blank">8114860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/26042815 /pubmed" id="26042815 " target="_blank">26042815 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956193">
<a name="33956193"></a>Yalçınkaya R, Öz FN, Kaman A, et al. Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years. <i>Eur J Pediatr</i>. 2021;180(8):2521-2527. doi:10.1007/s00431-021-04093-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/33956193/pubmed" id="33956193" target="_blank">33956193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GSK.2">
<a name="GSK.2"></a>Zovirax (acyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2019.</div>
</li>
<li>
<div class="reference">
                  Zovirax (acyclovir 200 mg, USP) oral suspension [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; April 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acyclovir-systemic-pediatric-drug-information/abstract-text/Mylan.1/pubmed" id="Mylan.1" target="_blank">Mylan.1</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15938 Version 649.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
